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ABSTRACT AND KEYWORDS
Autism spectrum disorders (ASD) are a cluster of neurodevelopmental disorders
characterized by abnormal social interactions, communication deficits, and repetitive
and restricted behaviours. Propionic acid (PPA), a component of fatty acid metabolism,
is endogenous to the human body, produced by enteric gut bacteria, and crosses both the
gut-blood and the blood-brain barrier. Previous research has demonstrated that repeated
intracerebroventricular (ICV) infusions of PPA in adult rats produce behavioural and
neuropathological changes similar to those seen in ASD patients. The current studies
further characterized this animal model, focusing on repetitive and perseverative
behaviours, through the use o f the hole-board apparatus. Adult male Long-Evans rats
received ICV infusions twice a day, 4 hours apart, of high-dose PPA (0.26 M), low-dose
PPA (0.052 M), or phosphate buffered saline (PBS) for 7 consecutive days. Locomotor
activity and nose poke behaviour were recorded daily in an automated open field
apparatus (Versamax) equipped with a 16 well hole-board for 30 minutes immediately
after the second infusion. In the first study, all wells remained empty. PPA treatment
increased locomotor and nose poking behaviour in a dose-dependent manner. In the
second study, relevant olfactory stimuli (i.e., clean and soiled bedding) was placed
within the wells as a means o f measuring perseverative behaviour. Both high- and lowdose PPA animals failed to modify their nose poking patterns, suggestive of
perseverative behaviour. This work further supports the face validity of the PPA rodent
model o f ASD by demonstrating that repetitive and perseverative behaviours, core
symptoms of autism, occur within PPA infused rats.

in

Keywords: autism spectrum disorder, hole-board apparatus, locomotor activity,
perseveration, propionic acid, repetitive behaviour
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Chapter 1

General Introduction

2
1.1 Autism Spectrum Disorders
Autism spectrum disorders (ASD) are a heterogeneous family of
neurodevelopmental disorders characterized by three core symptom domains: deficits in
communication, abnormal social interaction, and restricted and/or repetitive interests
and behaviours (American Psychiatry Association, 1994). Other symptoms include
hyperactivity, sensitivity to sensory stimuli, resistance to change, and cognitive deficits
in attention or memory (Kootz, Marinelli, & Cohen, 1982; Markram, Rinaldi, &
Markram, 2007; Murray, 2010; Sasson, Turner-Brown, Holtzclaw, Lam, & Bodfish,
2008). Furthermore, autism often co-exists with a variety of other conditions, including
fragile X syndrome, tuberous sclerosis, mental retardation, and epilepsy (Muhle,
Trentacoste, & Rapin, 2004; Tuchman, Moshe, & Rapin, 2009). Typically, autistic
symptoms become evident in children before 36 months of age (Rapin, 1997). Most
children who develop autism have early onset symptoms within the first year of life
characterized by abnormal social development (e.g., deficits in social smiling and eye
contact), delay in babbling, poor motor coordination, and repetitive motor actions
(Barbara & Dissanayake, 2009; Landa, 2008). About one-third o f cases are considered
late onset. Children appear to develop normally until about 2 years of age, at which
point social and communication skills regress to that of an autistic phenotype (Ozonoff,
Williams, & Landa, 2005)
Over the last decade, there has been nearly a 300% increase in the prevalence of
autism, with current estimates of approximately 1 in every 110 children affected with
autism, and males are four times more likely to be affected than females (Boyle et al.,
2011). Although the significant increase in ASD is at least partly due to better awareness
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and broadening diagnostic criteria, it is unlikely that this can solely account for the
substantial increased prevalence o f autism. In fact, several recent studies have provided
support for a true increase in disease frequency over the last several decades, unrelated
to changes in diagnostic criteria (Blaxill, 2004; Schechter & Grether, 2008). The rising
incidence of autism is a matter of urgent public concern. Unfortunately, the etiology of
autism is poorly understood and researchers do not fully understand the contributions of
genetics, biology, and the environment to the pathogenesis and on-going
symptomatology o f ASD. Thus, it is imperative that research examines the mechanisms
behind autism in order to better understand this complex disease. An effective way to
accomplish this is to develop an animal model. Animal models allow researchers to
examine the underlying mechanism/cause of a disease in a controlled manner that is
ethically impossible to do in humans. The major purpose of the current studies is to
provide further support for a rodent model of autism developed in our laboratory as a
means of furthering our understanding of the underlying pathophysiology of ASD.
1.1.1

Genetic and Environmental Aspects of ASD
Evidence from family and twin studies suggests a moderate to strong genetic

basis for ASD susceptibility. The reported heritability estimate for autism is as high as
90%, with a significantly higher concordance rate in monozygotic twins than dizygotic
twins (Bailey et al., 1995; Elallmayer et al., 2011). Moreover, there is a high recurrence
rate of autism such that in families with at least one case o f ASD, the prevalence of
autism within the family is 100 times higher than the general population (Rutter,
Silberg, O'Connor, & Simonoff, 1999). Autism is considered biologically and
phenotypically heterogeneous, and this variability is also apparent in genetic linkage
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studies which show numerous candidate genes in ASD populations (Geschwind, 2011).
Unfortunately, there is no single mutation attributed to causing ASD and no genes that
can serve as definitive biomarkers for the disorder (Scherer & Dawson, 2011). Thus,
there is a general agreement in the literature that ASD has a large genetic component,
but further research is required to translate genomic linkage discoveries into diagnostics
relevant for prevention and treatment.
Because genetics cannot fully account for the manifestation of autism,
researchers have become increasingly interested in environmental agents that may act
during critical developmental periods. Chemical toxins and infectious agents present in
the environment during prenatal and early postnatal periods have been implicated in the
pathogenesis o f ASD. For instance, children exposed to thalidomide, valproic acid, and
ethanol in utero have an increased risk of ASD (Ratajczak, 2011). Maternal infections
have also been identified as a risk factor for autism, with approximately 43% of mothers
with an autistic child experiencing a respiratory, urinary, or other infection during
pregnancy as compared to 26% of control mothers (Comi, Zimmerman, Frye, Law, &
Peeden, 1999). Fever, a common physiological response to infection, may be treated
with anti-pyretics, such as acetaminophen, during pregnancy. Anti-pyretics interfere
with normal immunological development in the brain, and may partially explain why
maternal infection during pregnancy leads to increased susceptibility to ASD in
offspring (Currenti, 2010). Maternal stress, maternal anti-bodies, heavy metals,
phthalates, organophosphate pesticides, and many other environmental factors are also
believed to play a role in the etiology of ASD (Ratajczak, 2011; Ronald, Pennell, &
Whitehouse, 2010). Although previously thought to be a causal environmental factor in
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ASD, numerous studies have failed to support a relationship between the mumpsmeasles-rubella (MMR) vaccine and autism (Honda, Shimizu, & Rutter, 2005; Homig et
al., 2008; Schultz et ah, 2008). It is likely that an interaction between genetic
predisposition and environmental factors results in the manifestation and severity of
ASD. Indeed, a growing number of environmentally responsive genes and pathways are
being identified in some autistic populations (Fatemi, 2008; Herbert, 2010)
1.1.2

Central Nervous System and Systemic Abnormalities in ASD
Although autism has been traditionally considered a strongly brain-based

disorder, emerging findings support the idea of ASD as a systemic disorder involving
immune and metabolic dysfunction that also affects the central nervous system (CNS)
(Chauhan & Chauhan, 2006; Herbert, 2005a). In particular, there is increasing evidence
for the role o f oxidative stress, antioxidant impairment, and chronic inflammatory
processes in ASD from childhood through adulthood (Anderson, Hooker, & Herbert,
2008). Recent studies of post-mortem brain tissue in patients with ASD revealed innate
neuroinflammatory changes characterized by reactive astrogliosis and activated
microglia in the cerebral cortex, white matter, and cerebellum (Morgan et ah, 2010;
Vargas, Nascimbene, Krishnan, Zimmerman, & Pardo, 2005). Cytokine protein arrays
also demonstrated elevations in proinflammatory cytokines , such as interleukin-6 (IL6), in both the brain tissue and cerebrospinal fluid of autistics. Interestingly, these
neuroinflammatory changes were observed in both adults and children with the disorder,
suggesting that neuroinflammation may be a permanent state o f pathology in ASD that
starts early. This immune dysfunction may be a potential mechanism for the
pathogenesis o f autism, given that glial cells are important in developing and mature
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nervous systems via their role in immune function, support of neurons, the integrity of
the blood-brain barrier (BBB), and myelination of neurons (Barron, 1995).
Besides an innate neuroinflammatory response and increased cytokines, other
CNS abnormalities have also been found in persons with ASD. Imaging and post
mortem studies have demonstrated that the brain of autistics is grossly normal, but other
subtle anatomic aberrations do exist (Bauman & Kemper, 2005). Young children with
autism (but not older) have unusually large brain volumes due to an overgrowth shortly
after birth followed by slowed growth a few years later (Herbert, 2005b). Compared to
controls, autistic brains show smaller neuronal cell size and increased cell packing
density in the limbic system (e.g. hippocampus and amygdala), a pattern consistent with
truncated development (Palmen, van Engeland, Hof, & Schmitz, 2004). Purkinje cell
size in the cerebellum has been shown to be consistently reduced in brain tissue of ASD
patients at autopsy (Fatemi et al., 2002). Additionally, elevated 3-nitrotyrosine levels (a
specific marker o f oxidative damage to proteins), has been documented in cerebellar
tissue in autism (Sajdel-Sulkowska, Lipinski, Windom, Audhya, & McGinnis, 2008).
Imaging studies o f autistics have also shown an overall increase in white matter
thickness, suggestive of an underlying glial dysfunction, as well as a widespread
reduction in the functional connectivity among brain regions (Hughes, 2007; Sokol &
Edwards-Brown, 2004; Stigler, McDonald, Anand, Saykin, & McDougle, 2011).
Various systemic abnormalities indicative of altered immune regulation and
oxidative stress have also been observed in autism. An association between ASD and
immune dysfunction has been supported by reports of increased incidence of
autoimmune disease in families with an autistic child and altered metabolism in immune
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cells in children diagnosed with ASD (Atladottir et al., 2009; Suh, Walsh, McGinnis,
Lewis, & Ames, 2008). Furthermore, analysis of plasma samples from autistic children,
as compared to controls, have shown elevated production of brain-derived neurotrophic
factor (BDNF) and tumour necrosis factor alpha (TNF-a) by peripheral immune cells
under mitogenic stimulation, suggestive o f an excessive innate immune response
(Enstrom et al., 2008; Jyonouchi, Sun, & Le, 2001). Oxidative stress has also been
implicated in ASD pathogenesis. At a cellular level, oxidative stress occurs when the
levels o f deleterious reactive oxygen species exceed the antioxidant and detoxification
capabilities o f that cell, which can result in mitochondrial dysfunction, abnormal
membrane lipids, inflammation, and DNA damage (Pardo & Eberhart, 2007). Indeed,
increased oxidative stress has been observed in autism, as demonstrated by increased
lipid peroxidation and decreased antioxidant proteins (e.g., glutathione and transferrin)
in the plasma o f children with autism (Chauhan, Chauhan, Brown, & Cohen, 2004;
James et al., 2006). Recent evidence has also suggested a role for metabolic dysfunction
in autism involving disordered fatty acid profiles and altered energy dynamics of the
mitochondria (Gargus & Imtiaz, 2008; Wiest, German, Flarvey, Watkins, & HertzPicciotto, 2009).
1.1.3

Gastrointestinal Factors of ASD
Although a gastrointestinal (GI) pathology specific and unique to autism has not

been identified, there appears to be a high degree o f comorbidity between
gastrointestinal disorders and ASD (Buie et al., 2010). A number of GI symptoms and/or
disorders have been reported in ASD patients, including diarrhea, abdominal pain,
constipation, bloating, gastroesophageal reflux, gastritis, inflammatory bowel disease,
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and celiac disease, among others (Bauman, 2010). Dietary factors are also associated
with the behavioural symptoms of ASD. Parents frequently report an increase in the
severity o f autistic symptoms in their child following the consumption of refined wheat
and dairy products, and an improvement in symptoms following the implementation of a
casein- and gluten-free diet (Jyonouchi, 2009). In support of these anecdotal reports, a
recent randomized controlled trial showed improvements in attention and reduced
hyperactivity in children with ASD after a gluten- and casein-free dietary intervention
(Whiteley et ah, 2010). Moreover, some children with ASD have intestinal lesions,
increased intestinal permeability, and pro-inflammatory cytokine responses against
dietary proteins similar (but not identical) to those observed in patients with known
dietary protein intolerance/allergy (de Magistris et al., 2010; Jyonouchi, Sun, & Itokazu,
2002; White, 2003).
The human intestinal tract contains an enormous microbial ecosystem, or gut
microbiota, that is partially responsible for maintaining human health via protective,
structural, and metabolic roles (Prakash, Rodes, Coussa-Charley, & TomaroDuchesneau, 2011). Disruption o f the normal gut microbiota has been associated with
various disease processes, including autoimmune and metabolic disorders (Mai &
Draganov, 2009). Analysis of stool specimens from autistic children with co-morbid GI
symptoms has shown evidence of abnormal gut microflora, particularly a greater
diversity and number of clostridial species (Finegold et al., 2002; Parracho, Bingham,
Gibson, & McCartney, 2005; Song, Liu, & Finegold, 2004). Another enteric organism,
Desulfovibrio, has also been shown to be more common in regressive cases of autism
(Finegold, 2011). Colonization with clostridial or other species may be facilitated by
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antibiotic use, which can disrupt the indigenous gut species and promote the overgrowth
o f antibiotic resistant pathogenic organisms (as is the case with both Clostridium and
Desulfovibrio). Indeed, a retrospective study by Niehus and Lord (2006) found that the
early medical history o f children with ASD included significantly more antibiotic use
than typically developing children. Recent evidence from studies in rodents has shown
that gut microbiota can modulate brain development and behaviour (Heijtz et al., 2011;
Li, Dowd, Scurlock, Acosta-Martinez, & Lyte, 2009). Abnormal gut microflora may
contribute to the pathogenesis of ASD in genetically sensitive subpopulations.
1.2. Propionic Acid
Propionic acid (PPA) is a component of fatty acid metabolism, and like other
short-chain fatty acids (SCFA), such as acetic and butyric acid, PPA is a metabolite of
microbial fermentation of undigested food in the colon (Al-Lahham, Peppelenbosch,
Roelofsen, Vonk, & Venema, 2010). Besides gut bacterial production, which contributes
to about 20% o f PPA sources in the body, PPA is also produced as a result of amino
acid (~50%) and odd-chain fatty acid (-30% ) catabolism (Thompson et al., 1990).
SCFAs comprise a significant metabolic energy source, and the metabolism of PPA, via
a series of steps, results in succinyl-CoA which can be incorporated directly into the
Krebs cycle (Al-Lahham et al., 2010). Certain families of enteric bacteria, including
propionibacteria and clostridia, are known to produce PPA (Femandez-Garcia &
McGregor, 1994; Finegold, Song, & Liu, 2002). In addition to these endogenous
sources, PPA is present in some food products that use bacterial fermentation in the
manufacturing process (e.g. dairy products, such as cheese and yogurt) and is commonly
used as a food preservative due to its anti-fungal properties (Brock & Buckel, 2004).
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However, it is important to note that these food sources contribute to only a small
proportion o f total PPA in the human circulation due to the large quantities produced by
bacterial fermentation in the gut (Cummings, Pomare, Branch, Naylor, & Macfarlane,
1987).
PPA has direct physiological effects on the GI tract, including altering gut
motility, increasing the contraction of colonic smooth muscle, dilating colonic arteries,
and activating mast cells (Karaki et al., 2006; Mitsui, Ono, Karaki, & Kuwahara, 2005).
As a weak organic acid, PPA can readily cross both the gut-blood and blood-brain
barriers passively or actively via monocarboxylate transporters where it can cross cell
membranes and accumulate within cells (Bergersen, Rafiki, & Ottersen, 2002). PPA is
capable of inducing widespread effects in the CNS, and can inhibit Na+/K+ ATPase,
increase NMDA receptor sensitivity, alter mitochondrial and fatty acid metabolism, and
affect immune activation and gene expression (Brass & Beyerinck, 1988; de MattosDutra et al., 2000; Parab, Nankova, & La Gamma, 2007; Wajner, Latini, Wyse, &
Dutra-Filho, 2004; Wyse et al., 1998). Furthermore, PPA can concentrate within cells,
resulting in intracellular acidification, which can alter neurotransmitter release, inhibit
gap junctions, and promote intracellular calcium release, all o f which can potentially
affect neuronal communication and behaviour (Remblier, Pontcharraud, Tallineau,
Piriou, & Huguet, 1999; Rorig, Klausa, & Sutor, 1996). Given the diverse physiological
effects on the GI tract and CNS, PPA may be a putative link between the dietary, GI,
and behavioural symptoms of ASD in genetically susceptible subpopulations.
Several findings suggest that PPA may be associated with the etiology and
pathogenesis of ASD. Propionic acidemia is a genetically acquired metabolic disorder
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which results in an accumulation of PPA caused by a deficiency of the mitochondrial
enzyme propionyl-coenzyme A carboxylase (Hofherr et al., 2009). Symptoms of
propionic acidemia include vomiting, loss of appetite, and motor, social, and language
delay, all o f which are reminiscent of autistic symptoms (Kaya et ah, 2008). In addition,
exposure to valproic acid may lead to increased levels of SCFAs such as PPA, and
valproic acid exposure early in development increases the likelihood of ASD (Omoy,
2009). As previously mentioned, some children with autism, particularly those with GI
symptoms and behavioural regression, have increased levels of enteric Clostridium and
Desulfovibrio, both o f which are known to increase levels of PPA and other SCFAs
(Finegold, 2011). Additionally, serum studies from autistic patients have shown
metabolic dysfunction consistent with PPA’s physiological effects, such as impairments
of glutathione and carnitine metabolism (Filipek, Juranek, Nguyen, Cummings, &
Gargus, 2004; James et ah, 2006).
The properties o f PPA led our laboratory to propose that alteration of PPA levels
or metabolism may be related to ASD, and therefore we recently investigated the effects
of exposure to PPA in rodents as a potential novel animal model of ASD. Repeated,
central infusions o f PPA in adult rats produced behavioural, biochemical,
electrophysiological, and neuropathological effects similar to those seen in human cases
of autism (MacFabe et ah, 2007, 2008). We found that intracerebroventricular (ICV)
infusions o f PPA in adult rats induced repetitive behaviours, kindled seizures,
hyperactivity, turning behaviour, and retropulsion, all of which bear resemblance to
symptoms seen in ASD (MacFabe et ah, 2007, 2008). Immunohistochemical analyses of
brain tissue in PPA-infused rodents revealed an innate neuroinflammatory response
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characterized by reactive astrogliosis and activated microglia, as well as increased
oxidative stress and decreased glutathione, in the absence o f any apoptotic cell loss
(MacFabe et al., 2007, 2008), which is consistent with autopsy studies of human autistic
patients (Bauman & Kemper, 2005; Vargas et ah, 2005). Furthermore, analysis of brain
lipid composition in PPA-infused rodents reveals altered phospholipid and acylcamitine
profiles similar to the abnormal lipid profiles seen in erythrocytes and plasma o f autistic
patients (Bell et ah, 2004; Thomas et ah, 2010)
Another set of studies found that central administration of PPA resulted in social,
cognitive, and sensorimotor impairments (Shultz et ah, 2008, 2009), lending further
credence to the face validity o f the PPA rodent model. Given the developmental and
systemic nature o f ASD, more recent work in our laboratory using the rodent model has
evaluated both central and systemic effects of PPA in adolescent and neonatal rats. Thus
far, our results have been consistent with symptoms observed in autistic patients, such as
object fixation in adolescent rats reminiscent of the restricted interests in ASD (for
review see Foley, Tichenoff, Ossenkopp, & MacFabe, 2010; MacFabe, Cain, Boon,
Ossenkopp, & Cain, 2011; Shams, Kavaliers, Foley, Ossenkopp, & MacFabe, 2009).
Finally, deuterium tracing o f PPA in rat brain has allowed our laboratory to confirm
PPA associated oxidative stress and edema (Nie et ah, 2011). Taken altogether, these
findings suggest that alterations in PPA metabolism may play a significant role in the
pathogenesis o f ASD, and supports the use of PPA in rodents as an effective model of
ASD.
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1.3 Present Studies
One of the core symptom domains of ASD is the presence o f stereotyped or
repetitive/restrictive behaviours (American Psychiatry Association, 1994). These
behaviours typically occur with high frequency and persist across the lifespan, at higher
rates and intensities than any other developmental disability (Esbensen, Seltzer, Lam, &
Bodfish, 2009; Matson, Dempsey, & Fodstad, 2009). Repetitive behaviour in ASD may
include motor stereotypies (e.g., hand flapping or body rocking), verbal rituals (e.g.,
repetitive questioning), and sometimes self-injurious behaviours (McDougle, Kresch, &
Posey, 2000; Muthugovindan & Singer, 2009). Restricted interests and resistance to
change (or perseverative behaviours) also characterize autism and may manifest as
inflexible adherence to routines or rituals, a limited number of interests and activities, a
behavioural need to preserve “sameness,” or preoccupation with part of an object or
objects (Kootz, Marinelli, & Cohen, 1982; Matson, Dempsey, & Fodstad, 2009).
Repetitive behaviours are apparent in a wide range of psychiatric disorders,
including obsessive compulsive disorder (OCD), attention deficit hyperactivity disorder
(ADHD) Tourette’s syndrome, and schizophrenia (Ridley, 1994), as well as in children
suffering from sensory impairments or severe intellectual disability (Barry, Baird,
Lascelles, Bunton, & Hedderly, 2011). Some of these disorders, such as OCD and
ADHD, are often co-morbid with autism (Leyfer et al., 2006). Furthermore, autism
spectrum traits have been found in children and adolescents diagnosed with OCD
(Ivarsson & Melin, 2008), suggesting that perhaps these disorders have common
etiologies, underlying biological mechanisms, or similarly affected brain regions.
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Although several studies have shown that dysfunction in the basal ganglia,
frontal cortex, and frontostriatal circuits are involved in the manifestation of repetitive
and perseverative behaviours seen in many psychiatric disorders, it is important to point
out that the repetitive and “sameness” behaviours seen in ASD are characteristically
different from those seen in OCD (Ridley, 1994; McDougle et al., 2000). Compared to
adults with OCD, autistic patients are more likely to engage in repetitive ordering,
hoarding, telling or asking, tapping, and self-damaging behaviours and are less likely to
engage in cleaning, checking, and counting behaviours that are common in patients with
OCD (McDougle et al., 1995; Zandt, Prior, & Kyrios, 2009). Additionally, adults with
autism had significantly more repetitive behaviours than repetitive thoughts, and no
autistic patient had repetitive thoughts alone. Few autistic patients made an active effort
to suppress or resist their repetitive behaviours. In contrast, nearly all patients with OCD
had both repetitive thoughts and behaviours, only a very small percentage (~ 0.5%) had
only repetitive behaviours, and 95% of OCD patients regarded the obsessions and
compulsions as intrusive and actively attempted to suppress the thoughts and resist the
behaviours.
The purpose o f the current studies is to further explore the core symptom domain
of repetitive and perseverative behaviours in ASD in the context of an animal model.
Animal models provide an opportunity to advance our understanding of the biological
mechanisms underlying autistic disorders (van der Staay, 2006). In order to extend the
validity o f the PPA rodent model of ASD proposed by our laboratory, it is essential to
test the model using behavioural assays relevant to the symptoms of autism (Crawley,
2007; MacFabe et al., 2007). One such behavioural task that is useful for assessing
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repetitive behaviour in rodents is the hole-board apparatus (File & Wardill, 1975;
Makanjuola, Hill, Maben, Dow, & Ashcroft, 1977; Moy et al., 2008). The hole-board
apparatus is an elevated platform with 16 equally spaced holes (with wells underneath)
that can be fitted into an open field chamber, allowing for measurement of both
locomotor activity and nose pokes (the measure specific to the hole-board). Although
not currently in widespread use as a behavioural test, research has shown that analysis of
nose pokes within the hole-board task can provide a valid and reliable measure of
exploratory and repetitive behaviours (File & Wardill, 1975a, 1975b). Furthermore,
Moy and colleagues (2008) demonstrated that using the hole-board task may be a useful
method o f assessing restricted and perseverative behaviours in rodents, particularly
when relevant olfactory stimuli are placed in the hole-board.
The aims of the current studies were to:
I.

Assess repetitive and perseverative behaviour following central PPA
treatment using the hole-board task

II.

Investigate the dose-response effects of PPA with a low-dose of PPA
(0.052 M) and a high-dose of PPA (0.26 M)

Both objectives were devised to further validate the use o f PPA as an effective rodent
model of ASD. The present studies are the first to investigate the effects of PPA using
the hole-board task, and the first to assess dose-related behavioural effects of PPA
treatment using a low-dose of PPA not previously used and comparing it to the “highdose” of PPA used in our previous experiments. Chapter 2 reports the dose-related
effects o f central administration of PPA on locomotor and nose poking behaviour in
adult rats when all wells within the hole-board were empty. It was expected that similar
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to previous work, PPA treatment would result in increased locomotor and repetitive
activity in a dose-dependent manner. The experiment in Chapter 3 was designed to
determine if placement of relevant olfactory stimuli (i.e., soiled and clean cage bedding)
within the hole-board would alter the pattern of hole-board exploration and whether
PPA-treated animals would adapt their behaviour in response to a change in the holeboard environment. Given that PPA-treated animals have shown a perseverative pattern
of responding in the water maze task (Shultz et al., 2009), it was expected that PPAtreated rodents in the hole-board task would fail to adapt their behaviour and that these
perseverative effects would be more pronounced in high-dose PPA animals than lowdose PPA animals. Chapter 4 provides a summary of both experiments as well as
implications and directions for future research.
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Chapter 2

Intracerebroventricular propionic acid results in a dose-dependent increase in
locomotor and nose poking behaviour in rats tested in an automated hole-board
apparatus: Support for an animal model of autism spectrum disorders
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2.1 Introduction
Autism spectrum disorders (ASD) are a cluster of neurodevelopmental disorders
affecting approximately 1 in 110 children, which represents a 300% increase in
prevalence over the last decade (Boyle et ah, 2011). The three main categories of
behavioural symptoms in ASD include impaired social interaction, communication
deficits, and restricted/repetitive interests and behaviours (American Psychiatry
Association, 1994). Other symptoms associated with autism include sensitivity to
sensory stimuli, hyperactivity, resistance to change, cognitive deficits, and seizures
(Kootz, Marinelli, & Cohen, 1982; Markram, Rinaldi, & Markram, 2007; Murray, 2010;
Sasson, Turner-Brown, Holtzclaw, Lam, & Bodfish, 2008). Although there is a strong
multigenetic basis for ASD susceptibility (Bailey et ah, 1995; Hallmayer et ah, 2011),
recent research suggests that environmental, dietary, and gastrointestinal factors may
play a role in the etiology and pathogenesis of autism (Ratajczak, 2011; Williams et ah,

2011).
Several findings suggest that exposure to propionic acid (PPA), a short-chain
fatty acid (SCFA) that is endogenous to the human body, may be associated with ASD.
PPA is an intermediary o f fatty acid metabolism and is a metabolic end-product of
microbial fermentation in the gut (Al-Lahham, Peppelenbosch, Roelofsen, Vonk, &
Venema, 2010; Thompson et al., 1990). Parents frequently report an increase in
behavioural symptoms when their autistic children ingest refined wheat and dairy
products (Jyonouchi, 2009), which contain PPA either as a result of the manufacturing
process (e.g., dairy) or as an additive food preservative (e.g., many wheat products)
(Brock & Buckel, 2004). Furthermore, consumption of these products can result in
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increased production of PPA via bacterial fermentation of undigested food within the
gut (Cummings, Pomare, Branch, Naylor, & Macfarlane, 1987). In support of these
anecdotal reports from parents, a randomized controlled trial showed improvement in
attention and reduced hyperactivity following implementation of a casein- and glutenfree diet in children with ASD (Whiteley et al., 2010). A subset of autistic children with
co-morbid gastrointestinal symptoms have abnormal gut microflora, including elevated
levels of Clostridium and Desulfovibrio, both of which are known to produce SCFAs
such as PPA (Finegold et al., 2002; Finegold, 2011; Parracho, Bingham, Gibson, &
McCartney, 2005). Exposure to valproic acid early in development, which can increase
levels o f PPA and other SCFAs, increases the likelihood of ASD (Omoy, 2009).
Furthermore, serum analysis in ASD patients has shown metabolic impairment of
glutathione, carnitine, and fatty acids consistent with the physiological effects of PPA
(Bell et al., 2004; Filipek, Juranek, Nguyen, Cummings, & Gargus, 2004; James et al.,
2006).
PPA is a weak organic acid, and can readily cross the gut-blood barrier and gain
access to the central nervous system (CNS) either passively across the blood-brain
barrier or via monocarboxylate transporters (Bergersen, Rafiki, & Ottersen, 2002). PPA
has widespread effects in the CNS including inhibition of Na+/K+ ATPase, increased
NMDA receptor sensitivity, alteration o f mitochondrial and fatty acid metabolism,
immune activation, and changes in gene expression (Brass & Beyerinck, 1988; de
Mattos-Dutra et al., 2000; Parab, Nankova, & La Gamma, 2007; Wajner, Latini, Wyse,
& Dutra-Filho, 2004; Wyse et al., 1998). In addition, PPA can accumulate within cells,
resulting in intracellular acidification which can alter neurotransmitter release, inhibit
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gap junctions, and promote intracellular calcium release, all of which can potentially
affect neuronal communication and behaviour (Remblier, Pontcharraud, Tallineau,
Piriou, & Huguet, 1999; Rorig, Klausa, & Sutor, 1996).
Our laboratory has proposed that alterations in PPA levels or metabolism might
be related to ASD and that administration of PPA in rodents may be a useful animal
model in which to further our understanding of the biological mechanisms underlying
ASD (MacFabe et al., 2007). Repeated, central infusions o f PPA in adult rats induced
hyperactivity, repetitive behaviours, kindled seizures, social impairments, cognitive
deficits, altered brain phospholipid profiles, increased oxidative stress, and an innate
neuroinflammatory response (MacFabe et ah, 2007, 2008; Nie et ah, 2011; Shultz et ah,
2008, 2009; Thomas et ah, 2010), consistent with findings from ASD patients (Bauman
& Kemper, 2005; Vargas, Nascimbene, Krishnan, Zimmerman, & Pardo, 2005; Wiest,
German, Harvey, Watkins, & Hertz-Picciotto, 2009). More recent work in our
laboratory investigating the systemic and developmental effects of PPA in adolescent
and neonatal rats has been consistent with the symptoms seen in autistic patients and
provides further validity to the PPA rodent model of autism (for review of these results
see Foley, Tichenoff, Ossenkopp, & MacFabe, 2010; MacFabe, Cain, Boon, Ossenkopp,
& Cain, 2011; Shams, Kavaliers, Foley, Ossenkopp, & MacFabe, 2009).
The current study aimed to extend previous findings of this animal model by
examining the central effects of two doses of PPA on locomotor and repetitive
behaviours in adult rats using the hole-board task. It was expected that PPA treatment
would produce increased locomotor and repetitive behaviour in a dose-dependent
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manner, similar to previous findings associated with PPA and consistent with symptoms
o f ASD.
2.2 Method
2.2.1

Subjects
Thirty-five naive male Long-Evans rats were used, weighing 200-225 g

(approximately 47-49 days old) at the time of arrival to the facility. Animals were
housed individually in standard rat polypropylene cages (W 26 x L 48 x H 21 cm) with
ad libitum access to food (LabDiet RMH 3000) and tap water in a temperaturecontrolled colony room (21 ± °C) on a 12:12 h light-dark cycle (lights on at 07:00 h).
Behavioural testing occurred during the light phase of the cycle. Animals were left
undisturbed for one week prior to the cannulation surgery. All procedures followed the
guidelines o f the Canadian Council on Animal Care and were approved by the
University o f Western Ontario Animal Use Subcommittee.
2.2.2

Apparatus
Locomotor activity was monitored using three Versamax Animal Activity

Monitors (AccuScan Model DCM-8, Columbus, OH, USA). Each monitor consisted of
a clear Plexiglas open field chamber (W 40 cm x L 40 cm x H 30.5 cm) and a clear
plastic lid with air holes. Movement was recorded via a grid of infrared beams located
on all four sides of the chamber for horizontal activity (16 equally spaced beams 2.54
cm apart and 4.5 cm from the floor) and a grid of infrared beams located on two sides of
the chamber for vertical activity (16 beams located 15 cm above the box floor). The
automated activity monitors were equipped with a hole-board on the floor of the
chamber to measure nose poke responses (see Figure 2.1A-D). The hole-board is an
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Figure 2.1. Photographs o f the automated activity monitors equipped with a hole-board
on the floor o f the chamber. (A) Side view; (B) Front view; (C) Top-down view; (D)
Top-down view with platform removed to show the 16 equally spaced wells beneath the
floor of the chamber.
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elevated platform with 16 equally spaced holes (2.54 cm diameter) with small wells
(5.08 cm diameter) underneath each hole. A set o f infrared beam sensors, separate from
those recording locomotor activity, are located between the well and the platform,
allowing for nose poke counts for each hole to be recorded via beam breaks. VersaMax
Analyzer software (Accuscan Model VSA-16, Columbus, OH) recorded data from each
automated activity monitor and relayed it to a computer that stored the data for
subsequent analysis. All sessions within the automated activity monitors were videorecorded and later reviewed to ensure accuracy o f the computer generated nose poke
data.
2.2.3

Procedure
2.2.3.1

Surgery. To induce anaesthesia, animals were placed into a sealed plastic

box into which 4% isoflurane at 2 L/min oxygen was introduced. The animal was then
placed into a Kopf stereotaxic device equipped with a gas flow mask delivering 2.5%
isoflurane at 500 mL/min o f oxygen to maintain anaesthesia during surgery. Under
aseptic conditions, right lateral ventricular cannulation surgery was performed (AP -1.4
mm, ML -1.8 mm, DV -3.0 mm). Each animal was implanted with a 23-gauge guide
cannula with the tip in the right lateral ventricle in accordance with a standard rat atlas
(Paxinos & Watson, 1998). The indwelling cannula was secured chronically using
dental acrylic anchored in place with small stainless steel screws inserted into the skull.
A removable obturator sealed the guide cannula and was only removed for infusions
during the experiment. Animals received a subcutaneous injection of analgesic
(ketoprofen, 1 mL/kg) immediately post-operatively. After surgery, animals were kept
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warm under a heating lamp until righting responses and locomotion returned. Animals
were housed individually and allowed two weeks recovery prior to testing.
2.2.3.2 Treatment groups and infusion procedure. Following recovery, animals
were randomly assigned to one o f three groups: high-dose PPA (0.26 M, 4.0 pL, n =
11), low-dose PPA (0.052 M, 4.0 pL, n = 9), or phosphate buffered saline vehicle (PBS,
4.0 pL, n = 15). Propionic acid was dissolved in PBS vehicle, and all solutions were
buffered to pH 7.5 using concentrated HCL or NaOH. Each animal received
intracerebroventricular (ICV) infusions twice daily (separated by 4 hours) for seven
consecutive days. The first infusion occurred during the light phase at 09:00 h. Solutions
were infused using a 30 gauge injection cannula that was connected to a Sage syringe
pump with sterile PE10 tubing. The tip o f the injection cannula protruded 0.5 mm
beyond the tip of the guide cannula. The syringe pump dispensed 4.0 pL o f solution
over a 60 s interval, and the injection cannula remained in place for an additional 60 s
before being removed.
2.2.3.3 Testing. Following two weeks of recovery, rats were handled and
habituated to the automated activity monitors for two days (30 minutes per day). On the
third day, baseline levels of activity and nose poke responses were recorded in the
absence o f infusion. During the seven treatment days, animals were placed in the
automated monitors following the second infusion of the day for 30 minutes to record
locomotor activity and nose poke counts (six 5 minute time bins). All wells within the
hole-board platform remained empty for the entire duration of behavioural testing
(including habituation, baseline, and testing days). Rats were weighed daily to monitor
health.
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2.2.3.4

Euthanasia. The day after behavioural testing was completed, rats were

euthanized via either intraperitoneal injection (euthanyl 270 g/mL, ~0.5 mL per animal)
or decapitation. Those euthanized by injection were transcardially perfused with a
PBS/4% paraformaldehyde solution. The fixed brains were removed and kept in a
sucrose solution for localization of the indwelling cannula. Animals that were
decapitated were later used for a lipid analysis study. Brains were quickly removed
following decapitation, frozen on dry ice, and stored in a -70 °C freezer until subsequent
lipid analysis. Whole blood collected from the trunk was spun in a centrifuge at 3000 x
g for five minutes and plasma was collected for lipid analysis.
2.2.4

Behavioural Measures
Locomotor activity was analyzed using eight distinct measures. The horizontal

activity measures analyzed were: total distance - total horizontal distance (cm)
travelled; horizontal movement time - amount o f time (s) an animal was engaged in
horizontal movement; and number o f horizontal movements - the number of horizontal
movements separated by a 1 s stop time. The vertical activity measures analyzed were:
vertical movement time - amount o f time (s) an animal spent in a vertical position; and
number of vertical movements - number of vertical movements separated by a 1 s stop
time. The repetitive locomotor measures were: clockwise revolutions - the numbers of
times an animal moved around in a clockwise circle of at least 2 inches in diameter;
counterclockwise revolutions - the number of times an animal moved around in a
counterclockwise circle of at least 2 inches in diameter; and the number of stereotypic
movements - repeated breaking of the same infrared beam separated by 1 sec or more.
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Nose poke behaviour was analyzed using total nose poke counts and hole
category. Total nose poke counts are the total number of nose pokes across an entire
testing session (includes all 16 different holes in the hole-board). Hole category data
classified the holes into three categories based on location within the open-field
apparatus in order to determine if there was a pattern of hole preference. The three hole
categories based on location included comer holes (1, 4, 13, and 16); centre holes (6, 7,
10, and 11), and wall holes (2, 3, 5, 8, 9, 12, 14, and 15) (see Figure 2.2). In order to
control for differences in total nose pokes, each hole category was calculated as a
percent o f total nose pokes for each rat (e.g., centre hole nose pokes divided by total
number o f nose pokes multiplied by 100).
2.2.5

Statistical Analysis
Data were analyzed for main effects and interactions using a repeated measures

split-plot analysis o f variance (ANOVA) with drug treatment (PBS, low-dose PPA, and
high-dose PPA) as the between-subjects factor and infusion day (7 infusions days) and
time block (six 5 minute time blocks) as the within subjects factors (with the exception
of hole category, which was analyzed with only infusion day as the within subjects
factor). The dependent variables were several locomotor variables and two nose poke
response variables. Separate statistical analyses were conducted for each variable. A
one-way ANOVA was conducted on the baseline data to ensure that there were no
individual differences prior to treatment days. For any variable in which the baseline
ANOVA indicated significant group differences, a repeated measures ANCOVA was
performed, using the baseline data as a co-variate. Where appropriate, post-hoc pair-
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Figure 2.2. Schematic of the hole-board numbering system in the automated activity
monitor, indicating four comer holes (1,4, 13, and 16), four centre holes (6, 7, 10, and
11), and eight wall holes (2, 3, 5, 8, 9, 12, 14, and 15).
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wise comparisons were conducted using Tukey's HSD or Sidak. Significance was set to
a = .05.
2.3 Results
2.3.1

Cannula Placement
For those animals that were perfused (low-dose PPA, n = 9; PBS, n = 3),

histological analysis showed that cannula tips were correctly located within the right
lateral ventricle in all animals (see Figure 2.3). Unfortunately, we were unable to verify
cannula placement in those animals that were decapitated (high-dose PPA, n = 11; PBS
n = 12).
2.3.2

Locomotor Variables
2.3.2.1 Baseline. A one-way ANOVA was performed on the baseline data for

each locomotor variable. The one-way ANOVAs were not significant for total distance
travelled, horizontal movement time, vertical movement time, or any of the repetitive
activity measures (number o f stereotypic movements, number of clockwise revolutions,
and number o f counterclockwise revolutions). Thus, there were no differences in
locomotor activity among the treatment groups for these behavioural measures prior to
the first infusion day. The one-way ANOVA was significant on baseline day for number
o f horizontal movements and number o f vertical movements; therefore, baseline data
were used as a covariate on infusion days for these variables.
2.3.2.2 Horizontal activity measures. Analysis revealed a significant day x
treatment interaction for number of horizontal movements (ANCOVA), F( 12, 186) =
3.25, p < .01, and horizontal movement time (ANOVA), F(12, 192) = 2.74, p < .05.
There was a significant main effect of treatment for total distance traveled (ANOVA),
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Figure 2.3. Representative photomicrograph showing proper cannula placement (arrow)
into the right lateral ventricle using an H&E stain
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F(2, 32) = 16.67,p < .001. In general, PPA infusions produced an increase in all three
horizontal activity measures that was dose dependent. High-dose PPA infused rats
travelled further, made more horizontal movements, and spent more time traveling
horizontally than PBS rats across infusion days. Low-dose PPA animals showed the
same effects as high-dose PPA animals, but not until later into the infusion schedule.
Post-hoc analyses were conducted to determine differences between treatment
groups across infusion days or across time. As seen in Figure 2.4A, high-dose PPA
animals made significantly more horizontal movements than both PBS animals (on
infusion days 2, and 4-7 (p < .05)), and low-dose PPA animals (on infusion day 2 (p <
.05)) across infusion days. Low-dose PPA animals made significantly more horizontal
movements than PBS animals on infusion days 6 and 7 (p < .05). There were no
significant differences among treatment groups for number o f horizontal movements on
infusion days 1 and 3.
Across the 30 minute testing sessions, the ANCOVA showed a significant time x
treatment interaction for number of horizontal movements, FT 10, 155) = 8.35,/? < .001.
Post-hoc analyses were conducted across the six 5 minute time bins for number of
horizontal movements. On infusion day 1, there were no significant differences among
groups during the entire 30 minute testing session (see Figure 2.4B). On infusion day 4,
low-dose PPA animals made significantly less horizontal movements than PBS animals
during the first 5 minutes {p < .05), and high-dose PPA animals made significantly more
horizontal movements than PBS animals between 20 and 25 minutes (p < .05; see Figure
2.4C). There were no significant differences among treatment groups for all other times
during the testing session. On infusion day 7, both PPA groups made significantly more
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A

B

Figure 2.4. Mean number o f horizontal movements + SEM across infusion days (A) or
across time (B. infusion day 1; C. infusion day 4; D. infusion day 7) in PBS (n = 15),
low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26M, n = 11) infused animals.
Means accompanied by different superscripts (i.e., a or b) indicate a significant
difference between treatment groups on that particular infusion day or that particular
time (p < .05; no superscripts indicate no significant difference between groups).
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horizontal movements than PBS animals between 10 and 15 minutes and between 20
and 30 minutes (p < .05; see Figure 2.4D). Low-dose PPA animals also made
significantly more horizontal movements than PBS animals between 5 and 10 minutes
(p < .05). For the first 5 minutes, and between 15 and 20 minutes, there were no
significant differences among treatment groups. In general (other than the first infusion
day), both PPA groups showed a slight decrease in number o f horizontal movements
across time within testing sessions, whereas, PBS animals showed a steep decline in
number o f horizontal movements across time within testing sessions.
A similar pattern was seen across infusion days for horizontal movement time as
for number o f horizontal movements (see Figure 2.5). High-dose PPA animals spent
significantly more time traveling horizontally than PBS animals on all but the first
infusion day (infusion days 2-7, p < .05). High-dose PPA animals also spent
significantly more time traveling horizontally than low-dose PPA animals on infusion
day 2 (p < .05). Low-dose PPA animals spent significantly more time traveling
horizontally than PBS animals toward the end of the infusion schedule (infusion days 6
and 7 , ( p < .05).
Post-hoc analyses for total distance traveled across infusion days were similar to
number o f horizontal movements and horizontal movement time. High-dose PPA
animals traveled significantly more than PBS animals on infusion days 2-7 (p < .05; see
Figure 2.6). High-dose PPA animals also traveled significantly more than low-dose PPA
animals on infusion day 3 {p < .05). Low-dose PPA animals traveled significantly more
than PBS animals on infusion days 4, 6, and 7 (p < .05). There were no significant
differences among treatment groups for total distance traveled on infusion day 1.
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Figure 2.5. Mean horizontal movement time (s) + SEM across infusion days in PBS (n =
15), low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26 M, n = 11) infused
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant
difference between treatments on that particular infusion day (p < .05; no superscripts
indicate no significant difference between groups).

46

Figure 2.6. Mean total distance traveled (cm) + S E M across infusion days in PBS (n =
15), low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26 M, n = 11) infused
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant
difference between treatments on that particular infusion day (p < .05; no superscripts
indicate no significant difference between groups).
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2.3.2.3

Vertical activity measures. The ANCOVA revealed a significant day x

treatment interaction for number of vertical movements, F(12, 186) = 2.40,/? < .05, but
no significant time x treatment interaction, F(10, 155) = .27, ns. Post-hoc analysis across
infusion days showed that low-dose PPA animals made significantly more vertical
movements than PBS animals on infusion days 4, 6, and 7 (/? < .05; see Figure 2.7).
High-dose PPA animals also made significantly more vertical movements than PBS
animals on infusion day 6. There were no significant differences among treatment
groups on infusion days 1-3, and 5.
For vertical movement time, the ANOVA showed a significant time x treatment
interaction, F(10, 160) = 6.49,/? < .001. There was no significant main effect of
treatment, F(2, 32) = 1.58, ns, or day x treatment interaction, F(12, 192) = .82, ns. Posthoc analysis across time and within a testing session revealed that on infusion day 1,
high-dose PPA animals had significantly shorter vertical movement time than PBS
animals during the first 5 minutes (/? < .05, data not shown). For the remaining 25
minutes, there were no significant differences among treatment groups for vertical
movement time. On infusion day 4, there were no significant differences among
treatment groups for vertical movement time during the entire 30 minute testing session
(data not shown). On infusion day 7, there were no significant differences among
treatment groups for vertical movement time for the first 20 minutes of the testing
session. During the remainder o f the testing session, low-dose PPA animals had
significantly longer vertical movement time than PBS (time 20-30,/? < .05) and highdose PPA animals (time 25-30, /? < .05, data not shown).
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Figure 2.7. Mean number of vertical movements + SEM across infusion days in PBS (n
= 15), low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26 M, n = 11) infused
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant
difference between treatments on that particular infusion day (p < .05; no superscripts
indicate no significant difference between groups).
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2.3.2.4

Repetitive activity measures. The ANOVA revealed a significant day x

treatment interaction for number of stereotypic movements, F( 12, 192) = 3.15,/? < .01.
Across days, the number of stereotypic movements depended on the treatment groups
(see Figure 2.8A). In general, both PPA groups showed an increase in the number of
stereotypic movements across infusion days; whereas, PBS animals remained relatively
constant in the number of stereotypic movements across infusion days. Post-hoc
analyses revealed that high-dose PPA animals made significantly more stereotypic
movements than both PBS animals (on infusion days 3-7 (p< .05)), and low-dose PPA
animals (on infusion days 3 and 6 (p < .05)). In addition, low-dose PPA animals made
significantly more stereotypic movements than PBS animals on infusion days 6 and 7 (p
< .05). There were no significant differences among treatment groups for number of
stereotypic movements on infusion days 1 and 2.
There was also a significant time x treatment interaction for number of
stereotypic movements, F(10, 160) = 8.30,/? < .001. Across time, PBS animals showed
a decrease in the number o f stereotypic movements. Both PPA groups showed a
decrease in the number o f stereotypic movements across time, but much more gradually
than PBS animals. Post-hoc analysis for infusion day 1 showed that low-dose PPA
animals made significantly fewer stereotypic movements than both PBS and high-dose
PPA animals between 15 and 20 minutes (p < .05; see Figure 2.8B). There were no
significant differences among treatment groups for number of stereotypic movements
during the remainder of the testing session. On infusion day 4, high-dose PPA animals
made significantly more stereotypic movements than PBS animals during the first 5
minutes (/? < .05) and between 20 and 25 minutes (/? < .05; see Figure 2.8C). There were
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Figure 2.8. Mean number o f stereotypic movements + SEM across infusion days (A) or
across time (B. infusion day 1; C. infusion day 4; D. infusion day 7) in PBS (n = 15),
low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26M, n = 11) infused animals.
Means accompanied by different superscripts (i.e., a, b, or c) indicate a significant
difference between treatment groups on that particular infusion day or that particular
time (p < .05; no superscripts indicate no significant difference between groups).
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no significant differences among treatment groups at any other times during the testing
session. On infusion day 7, high-dose PPA animals made significantly more stereotypic
movements than PBS animals during the entire 30 minute testing session (time 0-30,/? <
.05; see Figure 2.8D). Low-dose PPA animals also made significantly more stereotypic
movements than PBS animals in 3 time bins (time 0-5 and time 20-30,/? < .05).
The ANOVA revealed a significant main effect of treatment for clockwise
revolutions, F(2, 32) = 12.87,/? < .001, and counterclockwise revolutions, F(2, 32) =
12.15,/? < .001. There was no significant day x treatment interaction for either
clockwise, F( 12, 192) = 1.87, ns, or counterclockwise revolutions, F(12, 192) = 1.97, ns.
In general, PPA infusions produced an increase in revolutions that was dose dependant.
High-dose PPA animals made more clockwise and counterclockwise revolutions than
PBS animals across infusion days. Low-dose PPA animals showed similar effects, but
not until later into the infusion schedule.
Post-hoc analyses revealed an identical pattern across infusion days for
clockwise and counterclockwise revolutions. High-dose PPA animals made significantly
more clockwise and counterclockwise revolutions than PBS animals on infusion days 3
to 7 (/? < .05; see Figure 2.9 for clockwise revolutions). Low-dose PPA animals made
significantly more clockwise and counterclockwise revolutions than PBS animals on
infusion days 6 and 7 (/? < .05). There were no significant differences among treatment
groups for clockwise or counterclockwise revolutions on infusion day 1 or 2.
Across the 30 minute testing session, the ANOVA showed a significant time x
treatment interaction for clockwise revolutions, F(10, 160) = 2.87,/? < .05, but not for
counterclockwise revolutions, F(10, 160) = 1.81, ns. In general, PBS animals showed a
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Figure 2.9. Mean number of clockwise revolutions + SEM across infusion days in PBS
(n = 15), low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26 M, n = 11) infused
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant
difference between treatments on that particular infusion day (p < .05; no superscripts
indicate no significant difference between groups).
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sharp decline in number of clockwise revolutions across time within a testing session. In
contrast, high-dose PPA animals showed a more gradual decline in clockwise
revolutions within the first half of the testing session, and during the second half of the
testing session, the number of clockwise revolutions remained relatively stable. Lowdose PPA animals showed a pattern more consistent with PBS animals across time
within the first 3 infusion days, and then switched to a pattern similar to high-dose PPA
across time for the remainder of the infusion schedule. On infusion day 1, post-hoc
analyses showed that there were no significant differences among treatment groups for
number of clockwise revolutions during the first 20 minutes of the testing session. For
the remaining 10 minutes, high-dose PPA made significantly more clockwise
revolutions than PBS animals (p < .05; data not shown). On infusion day 4, high-dose
PPA animals made significantly more clockwise revolutions than PBS animals, but only
between 15 and 20 minutes (p < .05; data not shown). During the last infusion day, highdose PPA animals made significantly more clockwise revolutions than PBS animals for
2 time bins (time 5-10 and time 15-20 ,p < .05; data not shown). Low-dose PPA animals
made significantly more clockwise revolutions than PBS animals during the first 5
minutes (p < .05) and the last 15 minutes (p < .05).
2.3.3

Nose Poke Variables
2.3.3.1

Nose poke counts. The one-way ANOVA performed on the baseline data

for total nose poke counts revealed no significant group differences. Therefore, there
were no significant differences among treatment groups in number of nose pokes prior
to the first infusion day.
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The ANOVA revealed a significant day x treatment interaction across infusion
days for number of nose pokes, F( 12, 192) = 2.96, p < .01. As seen in Figure 2.10A,
PPA infusions resulted in a dose-dependent increase in number of nose pokes toward the
end o f the infusion schedule. Post-hoc analyses showed that high-dose PPA animals
made significantly more nose pokes than PBS animals on infusion days 5 and 6 {p <
.05). On infusion day 7, low-dose PPA animals made significantly more nose pokes than
PBS animals (p < .05). There were no significant differences among treatment groups
for number of nose pokes on infusion days 1 through 4.
There was a significant time x treatment interaction for number of nose pokes,
F(10, 160) = 5.11, p < .01. Across time within a testing session, PBS animals showed a
steep decrease in number of nose pokes. In contrast, high-dose PPA animals showed a
slower decrease in number of nose pokes across time. Low-dose PPA animals resembled
PBS animals across time for most of the infusion days, with the exception of infusion
days 6 and 7, where low-dose PPA animals showed a pattern more similar to high-dose
PPA animals across time. Post-hoc analysis on infusion day 1 showed that there were no
significant differences among treatment groups for number of nose pokes during the first
20 minutes o f the testing session (see Figure 2.10B). During the last 10 minutes, highdose PPA animals made significantly more nose pokes than PBS animals (p < .05). On
infusion day 4, high-dose PPA animals made significantly more nose pokes than PBS
animals during 2 time bins (time 10-15 and time 20-25, p < .05; see Figure 2.10C).
During the last infusion day, high-dose PPA animals made significantly more nose
pokes
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Figure 2.10. Mean number of nose pokes + SEM across infusion days (A) or across time
(B. infusion day 1; C. infusion day 4; D. infusion day 7) in PBS (n = 15), low-dose PPA
(0.052 M, n = 9), and high-dose PPA (0.26M, n = 11) infused animals. Means
accompanied by different superscripts (i.e., a or b) indicate a significant difference
between treatment groups on that particular infusion day or that particular time {p < .05;
no superscripts indicate no significant difference between groups).
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than PBS animals between 10 and 30 minutes (p < .05; see Figure 2.10D). Low-dose
PPA animals made significantly more nose pokes than PBS animals during the last 10
minutes of the testing session (p < .05).
2.3.3.2

Hole category. A one-way ANOVA was performed on the baseline data

for each hole category variable (i.e., comer, wall, and centre nose pokes). The ANOVAs
failed to reveal any significant group differences for any of the hole category variables.
The ANOVA revealed a significant main effect o f treatment for number of
comer nose pokes, F(2, 32) = 4.13 ,p < .05, but not for number of wall nose pokes, F( 2,
32) = 2.99, ns, or for number o f centre nose pokes, F(2, 32) = 2.15, ns. In general, all
treatment groups made a similar proportion of comer nose pokes, wall nose pokes, and
centre nose pokes (see Figure 2.11 A, B, and C, respectively). Post-hoc analysis for
number of corner nose pokes showed that PBS animals made significantly more comer
nose pokes (in proportion to total nose pokes) than high-dose PPA animals on infusion
days 4 and 6. On all other infusion days, there were no significant differences among
treatment groups for number of comer nose pokes.
2.4 Discussion
To summarize, the results from the present study indicated that centrally infused
PPA in adult male rats produced increased locomotor and nose poking behaviour in a
dose-dependent manner. In general, high-dose PPA animals were more hyperactive,
made more vertical movements, displayed more stereotypic and repetitive movements,
and nose poked more often than PBS animals across infusion days and across time.
Low-dose PPA animals showed similar effects to high-dose PPA animals, but not until
later into the infusion schedule. In particular, low-dose PPA animals showed locomotor
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Figure 2.11. Mean number o f comer nose pokes (A), wall nose pokes (B), or centre
nose pokes (C) expressed as a percent of total nose pokes + SEM across infusion days
in PBS (n = 15), low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26M, n = 11)
infused animals. Means accompanied by different superscripts (i.e., a or b) indicate a
significant difference between treatment groups on that particular infusion day {p < .05;
no superscripts indicate no significant difference between groups).
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activity levels similar to those of PBS animals at the start of the infusion schedule, but
gradually increased to levels comparable to those o f high-dose PPA animals by the end
o f the infusion schedule (i.e., infusion days 6 and 7). Additionally, analyses of hole
category data indicated that all treatment groups made a similar proportion of wall and
centre nose pokes. For comer nose pokes, PBS animals made proportionately more
comer nose pokes than both PPA groups, but only on infusion days 4 and 6.
The increase in locomotor activity and stereotyped/repetitive behaviour
following infusion o f PPA in the current study is consistent with, but not identical to,
previous work using the PPA rodent model (MacFabe et ah, 2007, 2008). Both the
current and previous work used the same chronic infusion schedule over seven days
(two infusions per day), as well as the same automated activity monitors to measure
locomotor activity. The PPA dose used by MacFabe and colleagues was identical to that
o f the high-dose PPA group used in the current experiment. Despite the similarities in
experimental design, the animals in the present investigation displayed much greater
levels o f horizontal activity than in previous work. This was true for both PBS control
animals and high-dose PPA animals. This is particularly notable for total distance
traveled. For instance, on infusion day 3, the mean total distance traveled was 2968 cm,
4357 cm, and 8086 cm for PBS, low-dose PPA, and high-dose PPA animals,
respectively. In contrast, previous work showed an approximate mean total distance
traveled of 1000 cm in PBS animals and 3700 cm in PPA animals on infusion day 3
(MacFabe et al., 2007). Unlike the horizontal movement measures, the vertical
movement measures and number of stereotypic movements in PBS and high-dose PPA
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animals in the current study were similar to that o f earlier work (MacFabe et al., 2008;
Thomas et al., 2010)
Given that the present experiment used the same strain and gender of rat (i.e.,
male Long-Evans) and the same dose and infusion regimen o f PPA (i.e., two infusions
per day for seven consecutive days), and that PBS animals also showed an increase in
horizontal activity measures, it is highly unlikely that the increase was due to a
fundamental difference in the ability of these particular rats to metabolize or compensate
for PPA infusions, as compared to rats used in previous work using this model. The
most plausible explanation for the increase in horizontal activity seen in the current
experiment is the addition of the hole-board on the floor of the automated activity
monitors. The hole-board was the only difference in experimental design in the current
study suggesting that exploration in the hole-board apparatus may influence overall
locomotor activity.
Several studies have shown that locomotor activity varies independently o f nose
poking in rodents (Abel, 1995; Durcan & Lister, 1989; File & Wardill, 1975a, 1975b),
but others have found no such dissociation or mixed results depending on drug treatment
(Kliethermes & Crabbe, 2006; Moy et al., 2008). Kliethermes and Crabbe showed that
although drug treatment resulted in similar effects on both locomotor and nose poking
behaviours at a group level, analysis at the individual level in untreated mice revealed
that these behaviours could vary independently. Overall, there appears to be a
complicated and equivocal relationship between nose poking and locomotion as
measured in the hole-board apparatus.
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Both PPA groups showed a decrease in locomotor behaviour within a 30 minute
testing session. This decrease could reflect PPA metabolism and is consistent with the
known 18 to 57 minute half-life of PPA when administered to rats (Brusque et al.,
1999). Across infusion days, low-dose PPA animals gradually reached levels of
locomotor activity and nose poking comparable to that o f high-dose PPA animals.
Chronic low doses of PPA eventually led to abnormal motor behaviour, suggesting that
compensatory mechanisms were unable to effectively counteract the effects of PPA.
These compensatory mechanisms may include increased synthesis of certain enzymes,
such as propionyl CoA decarboxylase which metabolizes PPA, or carbonic anhydrase
which helps maintain acid-base balance (Nguyen et ah, 2007; Schlue, Domer, Rempe, &
Riehl, 1991)
Propionic acid has several physiological/biochemical effects that alter neural
function which can account for the increased locomotor behaviour seen in PPA-infused
animals. PPA can inhibit Na+/ K+ ATPase, increase NMDA receptor sensitivity,
promote intracellular calcium release, and elevate nitric oxide, all of which can alter
neurotransmission in brain regions relevant to locomotor behaviour (de Mattos-Dutra et
ah, 2000; Wajner et ah, 2004; Wyse et ah, 1998).
As a weak organic acid, PPA can passively accumulate in CNS cells resulting in
a reduction in intracellular pH, which has many physiological consequences (Karuri,
Dobrowsky, & Tannock, 1993). Previous work in our laboratory has shown that PPA
and other short chain fatty acids (i.e., butyric acid and sodium acetate) produce similar
behavioural impairments, but the non-acidic analogue of PPA, 1-propanol, did not
produce behavioural impairments, suggesting that pH dependent mechanisms are an
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important component of the observed effects (MacFabe et al., 2007; Shultz et al., 2008,
2009; Thomas et al., 2010). Intracellular acidification of neurons is known to increase
the synthesis and release of several neurotransmitters that can influence locomotor
activity, including glutamate, dopamine, norepinepherine, and serotonin (Cannizzaro,
Monastero, Vacca, & Martire, 2003; Remblier et al., 1999; Severson, Wang, Pieribone,
Dohle, & Richerson, 2003). Furthermore, 3-nitropropionic acid, a derivative of PPA,
causes motor abnormalities and is used as a rodent model of Huntington’s disease,
emphasizing that intracellular pH reduction is linked to increased locomotor behaviour
(Brouillet, Jacquard, Bizat, & Blum, 2005).
Another consequence of intracellular acidification is a reduction in intercellular
coupling via the rapid and reversible closure of gap junctions (Rorig et al., 1996). Gap
junctions play a vital role in electrotonic transmission in brain areas involved in
locomotor activity, including the basal ganglia, prefrontal cortex, and hippocampal
formation (O’Donnell & Grace, 1997; Velazquez, Han, & Carlen, 1997). In addition,
intrastriatal infusions of gap junction blockers produce movement stereotypies in
rodents (Moore & Grace, 2002). Thus, the increased locomotor behaviour seen in PPA
treated rats could be a consequence o f the closure of gap junctions.
In addition to the abnormal locomotor behaviour observed in PPA treated
animals, there was also an increase in nose poking compared to controls. PPA infusions
led to a dose-dependent increase in nose poking toward the end of the infusion schedule.
Nose poking, sometimes referred to as head-dipping, has typically been interpreted as
representing exploratory behaviour or investigation of a novel environment (File &
Wardill, 1975a, 1975b). However, many researchers have argued that nose poking in the
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hole-board apparatus does not measure exploratory behaviour, but instead reflects the
anxiety state o f the animal (Takeda, Tsuji, & Matsumiya, 1998), an escape response
(Brown & Nemes, 2008), or stereotyped behaviour (Makanjuola, Hill, Maben, Dow, &
Ashcroft, 1977). The widespread opinions regarding what the hole-board task is actually
measuring in rodents are likely due, at least in part, to methodological differences.
Across studies, the hole-board apparatus often differs in total number of holes (usually 4
or 16), the location o f the holes (centrally, peripherally, or equally dispersed within the
floor of the apparatus), the diameter of the holes (allowing the rodent to either insert
only its nose, or its entire head), the depth of the hole (ranging from 1 cm to 20 cm), and
whether the hole-board is enclosed or open (occasionally the hole-board is used as an
elevated platform without walls). In addition, the amount of time that rodents are
observed within the hole-board apparatus ranges widely (e.g., 5 minutes, 10 minutes, 30
minutes, and 3 hours). The variability o f the hole-board apparatus has led to conflicting
interpretations of nose poking behaviour, and this underscores the need for a
standardized hole-board apparatus. To my knowledge, no study has acknowledged these
methodological differences, and in order for the hole-board test to be valid and useful, it
is imperative that these issues be addressed in the future.
Another important consideration in the interpretation of the hole-board task is
the complexity o f exploratory behaviour. When rodents are exposed to a novel
environment, they often exhibit exploratory behaviour, such as locomoting around the
environment or orienting toward novelty (Ballaz, 2009; Berlyne, 1950). Presumably,
exploratory behaviour allows the animal to gather relevant survival-related information
about the unfamiliar place, such as food sources, mating opportunities, or the presence
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o f predators. With continued exposure, the environment becomes familiar, and
exploration decreases as animals become habituated. Decreased exploratory behaviour
in response to repeated exposure to a novel environment is one of the most common
forms o f habituation seen in rodents, and habituation is often considered the simplest
form o f learning (Leussis & Bolivar, 2006). However, there are a variety o f factors
influencing exploratory behaviour, including arousal level, attention, learning, memory,
and fear o f novelty (Berlyne, 1969; Bronson, 1968). The presence of these mitigating
factors in exploratory behaviour makes the interpretation o f any measure of exploration
complex. Although levels o f nose poking may reflect exploratory behaviour, any
increase or decrease in nose poking following treatment may be due to a variety of
factors, suggesting that interpretation o f results may require complementary information
from evaluations of anxiety, learning and memory, etc.
Given the complexity of interpreting nose poking behaviour in the hole-board
apparatus, there are several possible explanations for the dose-dependent increase in
nose pokes following PPA infusion. Assuming that nose poking represents exploratory
behaviour, one possible explanation is that PPA infusions resulted in an increase in
exploratory behaviour secondary to cognitive deficits in learning and memory.
Intersession habituation, measured as a decrease in exploratory behaviour upon re
exposure to a novel environment, is considered to be an indicator o f learning and
memory (Leussis & Bolivar, 2006). Since PPA infusions resulted in an increase in
exploratory behaviour across testing sessions, this may indicate that PPA animals failed
to retain information about the novel environment. However, it is important to mention
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that control animals maintained a relatively stable level of nose poking across infusion
days, which would signify little or no habituation to the hole-board apparatus.
Another possible explanation for the results in the current study is that nose
poking may encompass both exploratory and repetitive behaviour. Makanjuola and
colleagues (1977) described exploratory behaviour as the overall pattern of nose pokes,
whereas repeated responses into one hole was considered a sign of stereotypy. The hole
category data from the current study allows for the assessment of the pattern of nose
pokes within the apparatus, and therefore exploratory behaviour. Overall, animals made
a similar proportion of comer, wall, and centre nose pokes. This suggests that PPA
infusions did not alter exploratory behaviour. Although the current study did not
measure repeated responses into one hole, the increase in nose poking seen in PPA
animals could plausibly result from repetitive patterns of nose poking. Studies using a
hole-board with 16 empty holes (similar to the current study), have shown that there is a
gradual transition from exploratory to stereotyped nose poking observed across time,
with most exploratory nose poking occurring within the first 10 minutes in the holeboard apparatus (Makanjuola et al., 1977; Makanjuola, Hill, Dow, Campbell, &
Ashcroft, 1977). This trend was seen in both control and drug-treated animals, with
control animals displaying some stereotyped nose poking (as defined by repeated
responses to one hole).
Results from the current study are consistent with this interpretation. PBS
animals displayed a relatively stable level of nose poking across infusion days. Across
time, PBS animals showed a marked decrease in nose poking after the first 10 minutes
within the hole-board apparatus. This suggests that in control animals, nose poking
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represented mostly an exploratory response, as opposed to a repetitive response in the
hole-board. In contrast, PPA infused animals showed an increase in nose poking
behaviour across infusion days, which corresponded with a relatively consistent level of
nose poking after the first 10 minutes within the apparatus, suggestive of a repetitive
response.
There are a number of ways in which PPA might affect brain function to cause
the behavioural impairments reported here. Histological examination of brain tissue in
rodents has shown that PPA can induce an innate neuroinflammatory response,
characterized by reactive astrogliosis and activated microglia in the hippocampus and
neocortical white matter (MacFabe et al., 2007). Neuroinflammation is also known to
occur in other diseases, such as Parkinson’s and Alzheimer’s disease, suggesting that
this response may impair normal cognitive processes (Ferretti & Cuello, 2011; Whitton,
2007). Activated microglia secrete cytokines and toxic substances (e.g., nitric oxide)
that are potentially damaging to neurons, which may impair brain function (Barron,
1995). However, fast-acting mechanisms caused by PPA, such as closure of gap
junctions and pH-dependent increases in serotonin, may also explain the behavioural
changes seen in the current study. Connexin-36 knock-out mice show deficits in normal
spatial coding and short-term spatial memory, suggesting that electrical coupling of
intemeurons in the hippocampus via gap junctions are important for spatial coding and
cognition (Allen, Fuchs, Jaschonek, Bannerman, & Monyer, 2011). Moreover, studies
have shown that 5-HT(l A) receptor agonists produce learning and memory deficits in
rodents (Ogren et ah, 2008). It is possible that a fast-acting mechanism combined with
neuroinflammation led to the behavioural impairments seen here.
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The synthesis and release of dopamine and serotonin following intracellular
acidification by PPA may explain the stereotyped nose poking behaviour seen in these
animals. Increases in both serotonin and dopamine in corticostriatal circuits of the brain
have been linked to stereotyped and repetitive behaviour in rodents (Langen, Kas, Staal,
van Engeland, & Durston, 2011) and humans (Langen, Durston, Kas, van Engeland, &
Staal, 2011). Indeed, studies using the hole-board apparatus suggest that some aspects of
the dopaminergic system are involved in nose poking behaviour (Kliethermes & Crabbe,
2006).
The findings from the current study indicate that PPA induces locomotor
behaviour and stereotyped/repetitive behaviour similar to the symptoms seen is ASD.
Individuals with ASD often display hyperactivity, motor stereotypies, and repetitive
behaviour (Matson, Dempsey, & Fodstad, 2009; Murray, 2010). Additionally, those
with ASD typically display decreased exploratory behaviour compared to normal
individuals when exposed to novel environments (Pierce & Courchesne, 2001). This is
contradictory to results seen in PPA-infused rodents, assuming that increased nose
poking should be considered increased exploratory behaviour, but this interpretation of
the hole-board task is still under considerable debate.
Importantly, the proposed mechanisms underlying the behavioural impairments
seen is PPA-infused animals are also theoretically linked to ASD. Aberrations in
dopamine and serotonin have been reported in autistic individuals (Chugani, 2004;
Previc, 2007), and treatment of repetitive behaviours has been shown to be effective
with serotonin reuptake inhibitors, and serotonin and dopamine antagonists (McDougle,
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Kresch, & Posey, 2000; McPheeters et al., 2011). An active neuroinflammatory process
has also been observed in those with ASD (Morgan et al., 2010; Vargas et al., 2005).
In conclusion, central infusions of PPA in adult male rats resulted in locomotor
abnormalities and increased repetitive behaviour compared to controls. The direct or
indirect physiological properties of PPA, such as intracellular acidosis and
neuroinflammatory changes, may be a plausible mechanism underlying these
behavioural effects. The current findings are consistent with the symptoms seen in
individuals with ASD, and taken together with previous findings using this model,
support the use of PPA in an animal model of autism. Further research at critical
developmental periods is needed to better understand the mechanisms responsible for
the behaviours produced by PPA treatment and their potential involvement in human
ASD.
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Chapter 3

Intracerebroventricular propionic acid induces perseverative behaviour in rats
tested in an automated hole-board apparatus: Support for an animal model of
autism spectrum disorders
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3.1 Introduction
The prevalence of autism spectrum disorders (ASD), a class of
neurodevelopmental disorders, has increased dramatically over the last several decades,
and currently affects approximately 1 in 110 children (Boyle et al., 2011). ASD is
characterized by three major behavioural symptom domains: communication deficits,
abnormal social interaction, and repetitive/restricted behaviours (American Psychiatry
Association, 1994). Other associated symptoms may include hyperactivity, sensitivity to
sensory stimuli, cognitive deficits, seizures, and gastrointestinal (GI) disturbances
(Kootz, Marinelli, & Cohen, 1982; Markram, Rinaldi, & Markram, 2007; Murray, 2010;
Tuchman, Moshe, & Rapin, 2009; Williams et al., 2011). ASD has traditionally been
viewed as a strongly genetic based disorder, however increasing evidence suggests that
environmental, dietary, and gastrointestinal factors may also be contributing factors
(Ratajczak, 2011; Williams et al., 2011).
Propionic acid (PPA) is a short-chain fatty acid (SCFA) endogenously produced
as an intermediary o f fatty acid metabolism and as a metabolite of bacterial fermentation
in the gut (Al-Lahham, Peppelenbosch, Roelofsen, Vonk, & Venema, 2010; Thompson
et al., 1990). In the GI tract, PPA is capable of altering gut motility, dilating colonic
arteries, and activating mast cells (Karaki et al., 2006; Mitsui, Ono, Karaki, &
Kuwahara, 2005). PPA is able to cross the gut-blood barrier and enter the systemic
circulation, where it can gain access to the central nervous system (CNS) by crossing the
blood-brain barrier by passive or active means (Bergersen, Rafiki, & Ottersen, 2002).
Once in the CNS, PPA has widespread effects including changes in neurotransmitter
synthesis and release, lipid metabolism, mitochondrial function, immune activation, and
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gene expression (Brass & Beyerinck, 1988; Parab, Nankova, & La Gamma, 2007;
MacFabe et al., 2008; Wyse et al., 1998). Furthermore, intracellular acidification, due to
PPA accumulation within cells, can alter neurotransmitter release, inhibit gap junctions,
and promote intracellular calcium release (Remblier, Pontcharraud, Tallineau, Piriou, &
Huguet, 1999; Rorig, Klausa, & Sutor, 1996). All of the CNS effects o f PPA have the
potential to affect neuronal communication and therefore behaviour.
PPA may be associated with the etiology and pathogenesis of ASD. Anecdotal
evidence from parents suggests a worsening o f behavioural symptoms following
consumption o f refined wheat and dairy products (Jyonouchi, 2009). A recent
randomized controlled trial of casein- and gluten-free diets in children with ASD
supports these anecdotal reports, with an improvement in some behavioural symptoms
following implementation of this diet (Whiteley et al., 2010). Interestingly, PPA is
present in dairy as a result of the manufacturing process and is used as a preservative in
refined wheat products, though PPA produced by enteric bacteria may also increase
following consumption o f these products (Brock & Buckel, 2004; Cummings, Pomare,
Branch, Naylor, & Macfarlane, 1987). A subset o f children with ASD, particularly those
with associated GI symptoms or behavioural regression, have increased levels o f the
enteric bacterial species Clostridium and Desulfovibrio, both of which are known to
produce PPA and other SCFAs (Finegold et al., 2002; Finegold, 2011; Parracho,
Bingham, Gibson, & McCartney, 2005). Valproic acid can elevate levels of SCFAs,
including PPA, and exposure to valproic acid early in development increases the risk of
ASD (Omoy, 2009). Although there are currently no studies directly measuring PPA in
ASD patients, there is indirect evidence linking PPA to autism, including metabolic
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impairment o f fatty acids and deficiencies in carnitine and glutathione, consistent with
PPA’s physiological effects (Bell et al., 2004; Filipek, Juranek, Nguyen, Cummings, &
Gargus, 2004; James et al., 2009).
The physiological effects of PPA and the evidence linking PPA to autism led our
laboratory to propose that alterations in PPA may be related to some o f the symptoms
seen in ASD, and therefore we recently investigated the effects of PPA treatment in
rodents as a potential animal model of ASD. We found that intracerebroventricular
(ICV) infusions o f PPA in adult rats resulted in hyperactivity, repetitive behaviours,
kindled seizures, social impairments, cognitive deficits, altered brain phospholipid
profiles, widespread oxidative stress, and an innate neuroinflammatory response
(MacFabe et al., 2007, 2008; Nie et al., 2011; Shultz et al., 2009, 2008; Thomas et al.,
2010). The behavioural, biochemical, electrophysiological, and neuropathological
effects following PPA treatment is consistent with human findings in ASD (Bauman &
Kemper, 2005; Vargas, Nascimbene, Krishnan, Zimmerman, & Pardo, 2005; Wiest,
German, Harvey, Watkins, & Hertz-Picciotto, 2009). In order to assess the effects of
PPA during development, our most recent work investigated the central and systemic
effects of PPA in adolescent and neonatal rodents, and thus far our results have been
consistent with symptoms seen in autistic patients and lend further credence to the PPA
rodent model o f ASD (for review o f these results see Foley, Tichenoff, Ossenkopp, &
MacFabe, 2010; MacFabe, Cain, Boon, Ossenkopp, & Cain, 2011; Shams, Kavaliers,
Foley, Ossenkopp, & MacFabe, 2009).
The goal o f the current study was to further validate this animal model and
extend the findings reported by Meeking and colleagues (2009), which assessed the
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effect o f central administration of two doses of PPA on locomotor and repetitive
behaviour in the hole-board task. In that study, PPA treatment resulted in a dosedependent increase in locomotor behaviour and nose poking behaviour (a measure of
repetitive behaviour from the hole-board apparatus), analogous to the symptoms of ASD
(Meeking, Foley, Tichenoff, Ossenkopp, & MacFabe, 2009). The current study also
assessed the effects of two doses of PPA using the hole-board apparatus, but unlike the
previous study, relevant olfactory stimuli (i.e. clean and soiled bedding, see Method)
was placed within the wells o f the hole-board apparatus as a means of measuring
perseverative behaviour. It was expected that PPA treatment would result in
perseveration, similar to previous findings associated with PPA and consistent with
symptoms of ASD.
3.2 Method
3.2.1

Subjects
Thirty-two naive male Long-Evans rats were used, weighing 200-225 g

(approximately 47-49 days old) at the time of arrival to the facility. Animals were
housed individually in standard rat polypropylene cages (W 26 x L 48 x H 21 cm) with
ad libitum access to food (LabDiet RMH 3000) and tap water in a temperaturecontrolled colony room (21 ± °C) on a 12:12 h light-dark cycle (lights on at 07:00 h).
Behavioural testing occurred during the light phase o f the cycle. Animals were left
undisturbed for one week prior to the cannulation surgery. All procedures followed the
guidelines o f the Canadian Council on Animal Care and were approved by the
University o f Western Ontario Animal Use Subcommittee.
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3.2.2

Apparatus
Locomotor activity was monitored using three Versamax Animal Activity

Monitors (AccuScan Model DCM-8, Columbus, OH, USA). Each monitor consisted of
a clear Plexiglas open field chamber (W 40 cm x L 40 cm x H 30.5 cm) and a clear
plastic lid with air holes. Movement was recorded via a grid of infrared beams located
on all four sides of the chamber for horizontal activity (16 equally spaced beams 2.54
cm apart and 4.5 cm from the floor) and a grid o f infrared beams located on two sides of
the chamber for vertical activity (16 beams located 15 cm above the box floor). The
automated activity monitors were equipped with a hole-board on the floor of the
chamber to measure nose poke responses (see Figure 3.1A-D). The hole-board is
an elevated platform with 16 equally spaced holes (2.54 cm diameter) with small wells
(5.08 cm diameter) underneath each hole. A wire mesh screen was placed over each well
(see Figure 3. ID). A set of infrared beam sensors, separate from those recording
locomotor activity, are located between the well and the platform, allowing for nose
poke counts for each hole to be recorded via beam breaks. VersaMax Analyzer software
(Accuscan Model VSA-16, Columbus, OH) recorded data from each automated activity
monitor and relayed it to a computer that stored the data for subsequent analysis. All
sessions within the automated activity monitors were video-recorded and later reviewed
to ensure accuracy of the computer generated nose poke data.
3.2.3

Procedure
3.2.3.1

Surgery. To induce anaesthesia, animals were placed into a sealed plastic

box into which 4% isoflurane at 2 L/min oxygen was introduced. The animal was then
placed into a Kopf stereotaxic device equipped with a gas flow mask delivering 2.5%
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Figure 3.1. Photographs o f the automated activity monitors equipped with a hole-board
on the floor o f the chamber. (A) Front view; (B) Top-down view; (C) Top-down view
with platform removed to show the 16 equally spaced wells beneath the floor of the
chamber; (D) Close-up o f wells with wire mesh screens.
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isoflurane at 500 mL/min of oxygen to maintain anaesthesia during surgery. Under
aseptic conditions, right lateral ventricular cannulation surgery was performed (AP -1.4
mm, ML -1.8 mm, DV -3.0 mm). Each animal was implanted with a 23-gauge guide
cannula with the tip in the right lateral ventricle in accordance with a standard rat atlas
(Paxinos & Watson, 1998). The indwelling cannula was secured chronically using
dental acrylic anchored in place with small stainless steel screws inserted into the skull.
A removable obturator sealed the guide cannula and was only removed for infusions
during the experiment. Animals received a subcutaneous injection of analgesic
(ketoprofen, 1 mL/kg) immediately post-operatively. After surgery, animals were kept
warm under a heating lamp until righting responses and locomotion returned. Animals
were housed individually and allowed two weeks recovery prior to testing.
3.2.3.2

Treatment groups and infusion procedure. Following recovery, animals

were randomly assigned to one of three groups: high-dose PPA (0.26 M, 4.0 pL, n =
11), low-dose PPA (0.052 M, 4.0 pL, n = 10), or phosphate buffered saline vehicle
(PBS, 4.0 pL, n = 11). Propionic acid was dissolved in PBS vehicle, and all solutions
were buffered to pH 7.5 using concentrated HCL or NaOH. Each animal received
intracerebroventricular (ICV) infusions twice daily (separated by 4 hours) for seven
consecutive days. The first infusion occurred during the light phase at 09:00 h. Solutions
were infused using a 30 gauge injection cannula that was connected to a Sage syringe
pump with sterile PE10 tubing. The tip o f the injection cannula protruded 0.5 mm
beyond the tip of the guide cannula. The syringe pump dispensed 4.0 pL of solution
over a 60 s interval, and the injection cannula remained in place for an additional 60 s
before being removed.

85
3.2.3.3 Testing. Following two weeks of recovery, rats were handled and
habituated to the automated activity monitors for two days (30 minutes per day). On the
third day, baseline levels of activity and nose poke responses were recorded in the
absence o f infusion. During the seven treatment days, animals were placed in the
automated monitors following the second infusion of the day for 30 minutes to record
locomotor activity and nose poke counts (six 5 minute time bins). All wells within the
hole-board platform remained empty with wire mesh screens for habituation, baseline,
and the first two treatments days. On treatment days 3 through 6, clean bedding was
placed in one centre well and soiled bedding was placed in another centre well (holes 6
and 11, counter-balanced within treatment groups, see Figure 2). All animals were
exposed to soiled bedding from one unfamiliar male rat (i.e., bedding from an
individually housed rat in a separate colony room soiled for 72 hours) on each of
treatment days 3 to 6. The soiled bedding was from a different unfamiliar male rat for
each particular treatment day (i.e., soiled bedding was used from 4 different unfamiliar
male rats, one for each of days 3 through 6). On the seventh treatment day, the soiled
bedding was from the experimental rat’s own cage (also soiled for 72 hours). Rats were
weighed daily to monitor health.
3.2.3.4 Perfusions. The day after behavioural testing was completed, rats were
euthanized via intraperitoneal injection (euthanyl 270 g/mL, ~0.5 mL per animal).
Animals were transcardially perfused with a PBS/4% paraformaldehyde solution. The
fixed brains were removed and kept in a sucrose solution for localization of the
indwelling cannula.
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3.2.4

Behavioural Measures
Locomotor activity was analyzed using eight distinct measures. The horizontal

activity measures analyzed were: total distance - total horizontal distance (cm)
travelled; horizontal movement time - amount of time (s) an animal was engaged in
horizontal movement; and number of horizontal movements - the number o f horizontal
movements separated by a 1 s stop time. The vertical activity measures analyzed were:
vertical movement time - amount of time (s) an animal spent in a vertical position; and
number of vertical movements - number o f vertical movements separated by a 1 s stop
time. The repetitive locomotor measures were: clockwise revolutions - the numbers of
times an animal moved around in a clockwise circle of at least 2 inches in diameter;
counterclockwise revolutions - the number of times an animal moved around in a
counterclockwise circle of at least 2 inches in diameter; and the number of stereotypic
movements - repeated breaking of the same infrared beam separated by 1 sec or more.
Nose poke behaviour was analyzed using total nose poke counts, hole category,
and difference scores. Total nose poke counts are the total number o f nose pokes across
an entire testing session (includes all 16 different holes in the hole-board). Hole category
data classified the holes into four categories based on location within the open-field
apparatus in order to determine if there was a pattern of hole preference. The four hole
categories based on location included comer holes (1,4, 13, and 16); centre holes (6, 7,
10, and 11), and wall holes (2, 3, 5, 8 9, 12, 14, and 15) (see Figure 3.2). In order to
determine preferences between the soiled and clean bedding across treatment days,
difference scores were calculated. The total number of nose pokes at the hole with soiled
bedding (SB) was calculated as a percent of total nose pokes for that particular testing
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Figure 3.2. Schematic o f the hole-board numbering system in the automated activity
monitor, indicating four comer holes (1,4, 13, and 16), four centre holes (6, 7, 10, and
11), and eight wall holes (2, 3, 5, 8, 9, 12, 14, and 15).
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session for each individual animal to control for differences in total nose pokes between
animals. The same was done for the hole with clean bedding (CB) and a nearby empty
hole (EH). The SB percent minus the CB percent is the difference score (SB-CB) that
determined the preference for soiled bedding (i.e., a positive score would indicated a
preference for soiled bedding) or the preference for clean bedding (i.e., a negative score
would indicate a preference for clean bedding). The SB percent minus the EH percent is
the difference score (SB-EH) that determined the preference for soiled bedding (i.e., a
positive score would indicated a preference for soiled bedding) or the preference for an
empty hole (i.e., a negative score would indicate a preference for an empty hole). The
CB percent minus the EH percent is the difference score (CB-EH) that determined the
preference for clean bedding (i.e., a positive score would indicated a preference for
clean bedding) or the preference for an empty hole (i.e., a negative score would indicate
a preference for an empty hole).
3.2.5

Statistical Analysis
Data were analyzed for main effects and interactions using a repeated measures

split-plot analysis of variance (ANOVA) with drug treatment (PBS, low-dose PPA, and
high-dose-PPA) as the between-subjects factor and infusion day (7 infusions days) and
time block (six 5 minute time blocks) as the within subjects factors (with the exception
o f nose poke counts, hole category, and difference scores, which were analyzed with
only infusion day as the within subjects factor). Hole category and difference score data
were analyzed using separate ANOVAs for each set of infusion days (i.e., days 1 to 2,
days 3 to 6, and day 7). The dependent variables were several locomotor and nose poke
variables. Separate statistical analyses were conducted for each variable. A one-way
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ANOVA was conducted on the baseline data to ensure that there were no individual
differences prior to treatment days. For any variable in which the baseline ANOVA
indicated significant group differences, a repeated measures ANCOVA was performed,
using the baseline data as a co-variate. Where appropriate, post-hoc comparisons were
conducted using Tukey's HSD or Sidak. Significance was set to a = .05.
3.3 Results
3.3.1

Cannula Placement
Histological analysis showed that cannula tips were correctly located within the

right lateral ventricle in all animals (see Figure 3.3).
3.3.2

Locomotor Variables
3.3.2.1 Baseline. A one-way ANOVA was performed on the baseline data for

each locomotor variable. The one-way ANOVAs were not significant for total distance
travelled, horizontal movement time, the vertical activity measures (number of vertical
movements and vertical movement time), or any of the repetitive activity measures
(number of stereotypic movements, number of clockwise revolutions, and number of
counterclockwise revolutions). Thus, there were no differences in locomotor activity
among the treatment groups for these behavioural measures prior to the first infusion
day. The one-way ANOVA was significant on baseline day for number of horizontal
movements; therefore, baseline data were used as a covariate on infusion days for this
variable.
3.3.2.2 Horizontal activity measures. The ANCOVA revealed a significant day x
treatment interaction for number of horizontal movements, F( 12, 168) = 6.48,/? < .001.
ANOVAs showed a significant main effect of treatment for horizontal movement time,
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Figure 3.3. Representative photomicrograph showing proper cannula placement (arrow)
into the right lateral ventricle using an H&E stain
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F(2, 29) = 21.64,p < .001, and for total distance traveled, F(2, 29) = 19.78,p < .001. In
general PPA infusions resulted in a dose dependent increase in horizontal activity
measures. Across infusion days, high-dose PPA animals made more horizontal
movements, spent more time travelling horizontally, and traveled further than PBS
animals. Low-dose PPA animals showed a moderate increase in these same measures
across infusion days, reaching somewhat similar levels as high-dose PPA animals by the
end o f the infusion schedule.
Post-hoc analyses were conducted to determine differences among treatment
groups across infusion days for number o f horizontal movements. As seen in Figure 3.4,
high-dose PPA animals made significantly more horizontal movements than both PBS
and low-dose PPA animals on infusion days 3 through 7 (p < .05). In addition, low-dose
PPA animals made significantly more horizontal movements than PBS animals on
infusion day 6 (p < .05). There were no significant differences among treatment groups
for number o f horizontal movements on infusions days 1 and 2.
Across the 30 minute testing sessions, there was a significant time x treatment
interaction for number o f horizontal movements, F(10, 140) = 14.15,/? < .001. Post-hoc
analyses were conducted across the six 5 minute time bins for each infusion day. On
infusion day 1, there were no significant differences among groups for number of
horizontal movements for the entire 30 minute testing session (data not shown). On
infusion day 4, high-dose PPA animals made significantly more horizontal movements
than both PBS animals during 3 time bins (time 10-15 and time 20-30, p < .05) and also
low-dose PPA animals during 2 time bins (time 20-30, p < .05; data not shown). There
were no significant differences among treatment groups for number o f horizontal
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Figure 3.4. Mean number of horizontal movements + SEM across infusion days in PBS
(n = 11), low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26 M, n = 11) infused
animals. Means accompanied by different superscripts (i.e., a, b, or c) indicate a
significant difference between treatments on that particular infusion day (p < .05; no
superscripts indicate no significant difference between groups).
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movements during the remainder of the testing session. On infusion day 7, high-dose
PPA animals made significantly more horizontal movements than PBS animals during
the last 25 minutes o f the testing session (time 5-30,/? < .05; data not shown). High-dose
PPA animals also made significantly more horizontal movements than low-dose PPA
animals between 15 and 20 minutes (p < .05) and between 25 and 30 minutes (p < .05).
Furthermore, low-dose PPA animals made significantly more horizontal movements
than PBS animals between 10 and 15 minutes (p < .05). In general, (other than the first
infusion day), high-dose PPA animals showed a very minor decrease in number of
horizontal movements across time within testing sessions; whereas, PBS animals
showed a sharp decrease. In contrast, low-dose PPA animals showed a moderate
decrease in number o f horizontal movements across time within testing sessions.
A similar pattern was also observed across infusion days for horizontal
movement time as for number o f horizontal movements. High-dose PPA animals spent
significantly more time moving horizontally than both PBS (infusion days 3-7,/? < .05)
and low-dose PPA animals (infusion days 4-6,/? < .05; see Figure 3.5A). Low-dose PPA
animals also spent significantly more time moving horizontally than PBS animals on
infusion day 7 (/? < .05). There were no significant differences among treatment groups
for horizontal movement time for the first two infusion days.
Across the 30 minute testing sessions, there was a significant time x treatment
interaction for horizontal movement time, F(10, 145) = 3.58,/? < .01. Post-hoc analyses
conducted across the six 5 minute time bins revealed that on infusion day 1, there were
no significant differences among treatment groups for horizontal movement time across
the entire testing session (see Figure 3.5B). On infusion day 4, high-dose PPA animals
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Figure 3.5. Mean horizontal movement time (s) + SEM across infusion days (A) or
across time (B. infusion day 1; C. infusion day 4; D. infusion day 7) in PBS (n = 11),
low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26M, n = 11) infused animals.
Means accompanied by different superscripts (i.e., a or b) indicate a significant
difference between treatment groups on that particular infusion day or that particular
time (p < .05; no superscripts indicate no significant difference between groups).

95
spent significantly more time moving horizontally than PBS animals during the entire 30
minute testing session (time 0-30,/? < .05; see Figure 3.5C). In addition, high-dose PPA
animals spent significantly more time moving horizontally than low-dose PPA animals
for the last 20 minutes of the testing session (time \0 -3 0 ,p < .05). On infusion day 7,
high-dose PPA animals spent significantly more time moving horizontally than PBS
animals during the entire testing session, with the exception of the first 5 minutes (time
5-30,p < .05; see Figure 3.5D). High-dose PPA animals also spent significantly more
time moving horizontally than low-dose PPA animals during the last 5 minutes of the
testing session (time 25-30,p < .05). In addition, low-dose PPA animals spent
significantly more time moving horizontally than PBS animals between 10 and 15
minutes (p < .05). Across time, all treatment groups showed a decrease in horizontal
movement time; however, the rate of decline depended on the treatment group. In
general, (other than the first infusion day), high-dose PPA animals showed a gradual
decrease, low-dose PPA animals showed a moderate decrease, and PBS animals showed
a sharp decrease in horizontal movement time across time and within a testing session.
All treatment groups had the most pronounced decrease in horizontal movement time
within the first 15 minutes of a testing session, while remaining relatively stable for the
last 15 minutes of a testing session.
Post-hoc analyses across infusion days for total distance travelled were similar to
number of horizontal movements and horizontal movement time. On infusion days 3
through 7, high-dose PPA animals traveled significantly further than PBS animals (p <
.05; see Figure 3.6). Furthermore, high-dose PPA animals traveled significantly further
than low-dose PPA animals on infusion days 4 and 6 (p < .05). Low-dose PPA animals
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Figure 3.6. Mean total distance traveled (cm) + S E M across infusion days in PBS (n =
11), low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26 M, n = 11) infused
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant
difference between treatments on that particular infusion day (p < .05; no superscripts
indicate no significant difference between groups).
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traveled significantly further than PBS animals on the last infusion day (p < .05). There
were no significant differences among treatment groups for total distance traveled on
infusion days 1 and 2.
3.3.2.3 Vertical activity measures. Due to a technical error with the locomotor
activity boxes, 5 PBS animals and 5 high-dose PPA animals were excluded from
statistical analyses for both vertical activity measures (i.e., high-dose PPA, 0.26 M, n =
5; low-dose PPA, 0.052 M, n = 10; PBS, n = 5). Analyses revealed no significant main
effects or interactions for number of vertical movements, or vertical movement time,
with the exception of a significant main effect of treatment for number of vertical
movements, F(2, 17) = 11.83,/? < .01. Post-hoc analyses across infusion days for
number of vertical movements revealed that high-dose PPA animals made significantly
more vertical movements than both PBS animals (infusion days 6 and l , p < .05), and
also low-dose PPA animals (infusion day 6, p < .05) toward the end of the infusion
schedule (data not shown).
3.3.2.4 Repetitive activity measures. Analyses showed a significant main effect
of treatment for number o f stereotypic movements, F{2, 29) = 19.26, p < .001. As seen
in Figure 3.7A, PPA infusions resulted in an increase in stereotypic movements for
high-dose animals, but not for low-dose animals. Post-hoc analyses across infusion days
showed that high-dose PPA animals made significantly more stereotypic movements
than PBS animals on infusion days 3 through 7 {p < .05). High-dose PPA animals also
made significantly more stereotypic movements than low-dose PPA animals on infusion
days 4 to 7 (p < .05). There were no significant differences among treatment groups for
number of stereotypic movements for infusion days 1 and 2.
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Figure 3.7. Mean number o f stereotypic movements + SEM across infusion days (A) or
across time (B. infusion day 1; C. infusion day 4; D. infusion day 7) in PBS (n = 11),
low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26M, n = 11) infused animals.
Means accompanied by different superscripts (i.e., a or b) indicate a significant
difference between treatment groups on that particular infusion day or that particular
time {p < .05; no superscripts indicate no significant difference between groups).
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There was also a significant time x treatment interaction for number of
stereotypic movements, F( 10, 145) = 9.84,/? < .001. Across time, high-dose PPA, lowdose PPA, and PBS animals showed a minor, moderate, and sharp decrease in number
of stereotypic movements, respectively. Post-hoc analyses across time within a testing
session showed that on infusion day 1, high-dose PPA animals made significantly more
stereotypic movements than both PBS and low-dose PPA animals between 5 and 10
minutes (/? < .05; see Figure 3.7B). Between 20 and 25 minutes, high-dose PPA animals
made significantly more stereotypic movements than low-dose PPA animals (/? < .05).
On infusion day 4, high-dose PPA animals made significantly more stereotypic
movements than PBS animals during 4 time bins (time 10-30,/? < .05; see Figure 3.7C).
Additionally, high-dose PPA animals made significantly more stereotypic movements
than low-dose PPA animals during 2 time bins (time 20-30,/? < .05). On infusion day 7,
high-dose PPA animals made significantly more stereotypic movements than PBS
animals during the last 20 minutes o f the testing session (time 10-30,/? < .05; see Figure
3.7D). High-dose PPA animals also made significantly more stereotypic movements
than low-dose PPA animals during the last 5 minutes of the testing session (time 25-30;
/ ?<• 05).
Analyses revealed a significant main effect o f treatment for clockwise, F(2, 29)
= 12.51,/? < .001, and counterclockwise revolutions, F(2, 29) = 14.00,/? < .001. There
were no significant day x treatment or time x treatment interactions for clockwise and
counterclockwise revolutions. In general, high-dose PPA animals made more
revolutions than PBS animals. In contrast, low-dose PPA animals were similar to PBS
animals for number of revolutions. Post-hoc analyses conducted across infusion days
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showed that high-dose PPA animals made significantly more clockwise revolutions than
PBS animals (infusion days 3 to 7, p < .05; see Figure 3.8) and low-dose PPA animals
(infusion days 1, and 4 to 7, p < .05). A somewhat similar pattern was seen across
infusion days for counterclockwise revolutions (data not shown). High-dose PPA
animals made significantly more counterclockwise revolutions than PBS (infusion days
3, 4, 6, and 7,p < .05) and low-dose PPA animals (infusion days 4 and 6 ,p < .05).
3.3.3

Nose Poke Variables
3.3.3.1 Nose poke counts. The one-way ANOVA performed on the baseline data

for total nose poke counts failed to show any significant effects. Therefore, there were
no significant differences among treatment groups in number of nose pokes prior to the
first infusion day.
Analysis revealed a significant main effect of treatment for number of nose
pokes, F(2, 29) = 4.49, p < .05. As seen in Figure 3.9, PPA infusions resulted in an
increase in number of nose pokes, but post-hoc analyses across infusion days showed no
significant differences among treatment groups on any infusion day except day 6 where
low-dose PPA animals made significantly more nose pokes than PBS animals (p < .05).
3.3.3.2 Hole category. A one-way ANOVA was performed on the baseline data
for each hole category variable (i.e., comer, wall, and centre nose pokes). The ANOVA
was not significant for number of comer or wall nose pokes, but was significant for
number o f centre nose pokes. Therefore, baseline data was used as a covariate for
analysis for centre nose pokes.
The ANOVAs for comer nose pokes and wall nose pokes on infusion days 1 and
2 and infusion days 3 through 6 showed no significant main effect of day or main effect
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Figure 3.8. Mean number o f clockwise revolutions + SEM across infusion days in PBS
(n = 11), low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26 M, n = 11) infused
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant
difference between treatments on that particular infusion day (p < .05; no superscripts
indicate no significant difference between groups).
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Figure 3.9. Mean number of nose pokes + SEM across infusion days in PBS (n = 11),
low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26 M, n = 11) infused animals.
Means accompanied by different superscripts (i.e., a or b) indicate a significant
difference between treatments on that particular infusion day (p < .05; no superscripts
indicate no significant difference between groups).
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of treatment and no significant day x treatment interaction. On infusion day 7, the one
way ANOVAs for comer nose pokes and wall nose pokes showed no significant
treatment effects. The ANCOVA for centre nose pokes on infusion days 1 and 2
revealed a day x treatment interaction, F(2, 28) = 3.50,p < .05. However, post-hoc
analyses across infusion days showed no significant differences among treatment groups
for number of centre nose pokes for infusion days 1 and 2. The ANCOVA for centre
nose pokes on infusion days 3 through 6 showed no significant main effect of day or
main effect of treatment and no significant day x treatment interaction. On infusion day
7, the ANCOVA for centre nose pokes showed no significant treatment effects.
In summary, all treatment groups made a similar proportion of comer nose
pokes, wall nose pokes, and centre nose pokes (see Figure 3.10A, B, and C,
respectively) across infusion days. However, the proportion of nose pokes changed
substantially from infusion days 1 and 2, to infusion days 3 through 7. For comer and
wall nose pokes, the proportions decreased from infusion day 2 to 3; whereas, for centre
nose pokes the proportions increased.
3.3.3.3 Hole preference. The repeated measures ANOVAs for the SB-CB
difference score (i.e., soiled bedding percent minus clean bedding percent; see Method
section for details) on infusion days 1 and 2 and infusion days 3 through 6 showed no
significant main effect o f day or main effect o f treatment and no significant day x
treatment interaction. On infusion day 7, the one-way ANOVA for the SB-CB
difference score showed that the effect of treatment was significant, F(2, 29) = 5.56, p <
.01. Post-hoc analyses among treatment groups revealed that both PPA groups had
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Figure 3.10. Mean number of comer nose pokes (A), wall nose pokes (B), or centre
nose pokes (C) expressed as a percent of total nose pokes + SEM across infusion days
in PBS (n = 11), low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26M, n = 11)
infused animals. Means accompanied by different superscripts (i.e., a or b) indicate a
significant difference between treatment groups on that particular infusion day (p < .05;
no superscripts indicate no significant difference between groups.
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had significantly higher SB-CB difference scores than PBS animals (p < .05; see Figure
3.11).
The repeated measures ANOVAs for the SB-EH difference score (i.e., soiled
bedding percent minus empty hole percent; see Method for details) on infusion days 1
and 2 and infusion days 3 through 6 showed no significant main effect of day or main
effect o f treatment and no significant day x treatment interaction (data not shown). On
infusion day 7, the one-way ANOVA for the SB-EH difference score showed no
significant treatment effects (data not shown).
The repeated measures ANOVA for the CB-EH difference score (i.e., clean
bedding percent minus empty hole percent; see Method for details) on infusion days 1
and 2 showed a main effect of day, F( 1, 29) = 6.18, p < .05. Neither the main effect of
treatment, F(2, 29) = .79, ns, nor the day x treatment interaction, F(2, 29) = .59, ns, were
significant. Post-hoc analyses showed no significant differences among treatment groups
for CB-EH preference on infusion days 1 and 2 (see Figure 3.12). The repeated
measures ANOVA for the CB-EH difference score on infusion days 3 through 6 showed
a day x treatment interaction, F{6, 87) = 3.05, p < .01. Post-hoc analyses revealed that
low-dose PPA animals had significantly greater CB-EH difference scores than high-dose
PPA animals on infusion day 5 (p < .05; see Figure 3.12). On infusion day 7, the one
way ANOVA for the CB-EH difference score showed a significant effect of treatment,
F(2, 29) = 4.84, p < .05. Post-hoc analysis showed that PBS animals had significantly
higher CB-EH difference scores than both PPA groups on infusion day 7 (p < .05; see
Figure 3.12).
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Figure 3.11. Mean difference score (SB-CB) + SEM across infusion days in PBS (n =
11), low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26M, n = 11) infused
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant
difference between treatment groups on that particular infusion day {p < .05; no
superscripts indicate no significant difference between groups). The total number of
nose pokes at the hole with soiled bedding (SB) was calculated as a percent of total nose
pokes for that particular infusion day for each individual animal. The same was done for
the hole with clean bedding (CB). The SB percent minus the CB percent is the
difference score (SB-CB) that determines the preference for soiled bedding (i.e., a
positive score indicates a preference for soiled bedding) or the preference for clean
bedding (i.e., a negative score indicates a preference for clean bedding).
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Figure 3.12. Mean difference score (CB-EH) + SEM in PBS (n = 11), low-dose PPA
(0.052 M, n = 10), and high-dose PPA (0.26M, n = 11) infused animals. Means
accompanied by different superscripts (i.e., a or b) indicate a significant difference
between treatment groups on that particular infusion day (p < .05; no superscripts
indicate no significant difference between groups). The total number o f nose pokes at
the hole with clean bedding (CB) was calculated as a percent of total nose pokes for that
particular infusion day for each individual animal. The same was done for the empty
hole (EH). The CB percent minus the EH percent is the difference score (CB-EH) that
determines the preference for clean bedding (i.e., a positive score indicates a preference
for clean bedding) or the preference for an empty hole (i.e., a negative score indicates a
preference for an empty hole).
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3.4 Discussion
The present results indicate that PPA treatment increased locomotor and
repetitive activity and induced perseverative behaviours in adult rats. Abnormalities in
locomotor activity were most apparent in the high-dose PPA group, which showed
hyperactivity and repetitive movements compared to control animals across infusion
days and across time. Low-dose PPA animals had an overall trend of increased
locomotor activity compared to control animals, with the most prominent effects
observed toward the end of the infusion schedule. However, these increases were
moderate, and not as pronounced as high-dose PPA animals. Treatment with either dose
of PPA resulted in a general increase in nose poking behaviour. Additionally, PPAinfused animals failed to modify their behavioural patterns in the hole-board test on
infusion day 7, as observed by a persistent preference for the hole containing soiled
bedding.
Hyperactivity following PPA treatment in the current study, as measured by
horizontal activity measures, is consistent with previous work in our laboratory using
the same infusion schedule and dose o f PPA (0.26M twice daily for seven days)
(MacFabe et al., 2007, 2008). However, both PBS and high-dose PPA animals showed
considerably greater levels o f horizontal locomotion across infusion days than rodents
from respective treatment groups in previous experiments. In contrast, vertical and
repetitive movement measures in control and high-dose PPA animals were similar to
that of earlier work (MacFabe et ah, 2008; Thomas et ah, 2010). The addition of the
hole-board to the automated activity monitors may explain the reason for the overall
increase in horizontal movement seen across treatment groups, especially given relevant
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olfactory stimuli was present in the wells for most of the infusion schedule.
Accordingly, it may be worthwhile to assess locomotor behaviour without the holeboard in low-dose PPA animals in future experiments using this model, as the 0.052 M
PPA dose was used for the first time in the current study.
Locomotor behaviour in PPA treated animals decreased over a 30 minute testing
session, which is congruent with the known half-life of PPA when administered to rats
(Brusque et ah, 1999), although the decrease in locomotor behaviour across time could
be a result of habituation to the automated activity monitors. Low-dose PPA animals had
gradual, albeit moderate, increases in locomotor activity across infusion days,
suggesting that chronic low doses of PPA may have led to a decline in physiological
mechanisms that metabolize or clear PPA. Such physiologic compensatory mechanisms
may include synthesis o f metabolizing or pH balancing enzymes, such as propionyl CoA
decarboxylase or carbonic anhydrase, respectively (Nguyen et al., 2007; Schlue, Domer,
Rempe, & Riehl, 1991).
In addition to a dose-dependent increase in locomotor activity, PPA treatment
also led to a general increase in nose poking behaviour (e.g., a main effect of treatment
on nose poking behaviour), that, unlike locomotor activity, was not dose-dependent.
However, post-hoc analyses showed that with the exception of infusion day 6 (where
low-dose PPA animals made significantly more nose pokes than PBS animals), PPA
animals did not nose poke significantly more than PBS animals on any particular
infusion day. The interpretation of the general increase in nose poking following PPA
treatment is somewhat complex. Nose poking is usually described as a measure of
exploratory behaviour, which is influenced by several mitigating factors including level

110
o f arousal, learning and memory, and attention (Berlyne, 1969; Bronson, 1968; File &
Wardill, 1975). Others have proposed that nose poking represents an anxiety/escape
response or stereotyped behaviour (Makanjuola, Hill, Maben, Dow, & Ashcroft, 1977;
Takeda, Tsuji, & Matsumiya, 1998). Another possibility, suggested by Makanjuola and
colleagues (1977), is that the overall pattern of nose poking within the hole-board
represents exploratory behaviour, whereas repeated nose poking at one particular hole
represents repetitive/stereotyped behaviour. Thus, the hole category analysis used in the
current study, which assessed the pattern o f nose poking within the apparatus, may be a
better indicator o f overall exploratory activity. All treatment groups showed similar
patterns of hole-board exploration, as indicated by the proportion of comer, wall, and
centre nose pokes, suggesting that PPA treatment did not alter exploratory behaviour.
Although not measured here, the overall increase in nose poking seen in PPA animals
could plausibly result from repetitive patterns of nose poking, but hyperactivity cannot
be entirely ruled out.
PPA treatment also resulted in a persistent pattern of responding as indicated by
hole preference data (i.e, SB-CB and CB-EH difference scores). All treatment groups
preferred investigating the hole with soiled bedding over the hole with clean bedding
from infusion day 3 through 6. In addition, animals in all treatment groups showed
greater interest in the hole with clean bedding over an empty hole on infusion day 3, but
this interest declined to infusion day 6 (with the exception of the low dose PPA group on
infusion day 5). The most interesting finding is seen on infusion day 7, when the
animal’s own soiled bedding was used. On infusion day 7, PBS animals reversed their
hole preference, showing a preference for the hole with clean bedding over the hole with
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soiled bedding, whereas both PPA groups show a preserved interest in the hole with
soiled bedding. This is also apparent in the CB-EH difference score for infusion day 7,
where PBS animals showed a renewed interest in the hole with clean bedding
(comparable to that on infusion day 3 when the bedding was first introduced into the
apparatus). In contrast, on infusion day 7 both PPA groups somewhat maintained their
levels o f interest in the clean bedding hole over the empty hole comparable to infusion
day 6.
Although it is clear that PPA treatment resulted in a persistent behavioural
response on infusion day 7, it is not entirely clear whether this perseveration reflects a
social deficit (and/or an olfactory deficit) or a true cognitive deficit (e.g., in learning and
memory). Rodents rely on olfaction to obtain information about their environment, and
this is particularly important for social behaviour (Miranda, Ortiz-Godina, & Garcia,
2009). The soiled bedding used in this experiment has inherent olfactory information
that is socially relevant. As a result, the persistent pattern of responding in PPA-infused
animals could represent a deficit in social information processing. Alternatively, the
perseveration may be due to an olfactory deficit in which PPA treated animals cannot
distinguish between their own odour and that of a novel conspecific.
The perseverative effect of PPA treatment is also consistent with a cognitive
deficit interpretation. The results of the current study are similar to the cognitive
impairments in learning and memory observed in previous work using the PPA rodent
model (MacFabe, Cain, Boon, Ossenkopp, & Cain, 2011; Shultz et al., 2009). PPAtreated adult or adolescent rats were not impaired during the acquisition phase o f the
water maze or T-maze, respectively, but were impaired during the reversal phase.

112
Similarly, PPA-treated animals in the present study were comparable to control animals
during the initial exposure to soiled and clean bedding within the hole-board apparatus,
but failed to change their behavioural response on infusion day 7 when the environment
required a different directional response. The lack of impairment during initial exposure
to the hole-board apparatus suggests that the cognitive mechanisms required for
processing information within the task were not impaired by PPA.
Importantly, the perseverative behaviours seen in PPA treated animals do not
appear to be related to other factors, such as baseline hole preference differences, an
inability to distinguish between soiled and clean bedding, or a lack of exploration of the
hole-board apparatus. There was no significant difference between treatment groups for
hole preference (i.e., SB-CB, SB-EH, and CB-EH difference scores) on infusion days 1
and 2, when all wells were empty, suggesting that there were no baseline differences in
hole preference. All treatment groups showed an increase in nose poking on infusion
day 3, when clean and soiled bedding was initially placed in the apparatus. Placement of
bedding in the centre holes led to a change in the pattern o f hole-board exploration for
all treatment groups. Specifically, the proportion o f centre nose pokes increased
dramatically. Additionally, all treatment groups had similar hole preferences from
infusion day 3 to 6. Taken together, this suggests that PPA animals were capable of
distinguishing between soiled and clean bedding. However, this does not completely
rule out that PPA treatment led to more subtle olfactory deficits that made it difficult for
animals to differentiate between their own and an unfamiliar male rat’s soiled bedding.
All treatment groups made a similar proportion of comer, wall, and centre nose pokes
across infusion days, suggesting that both PPA groups had hole-board exploration
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similar to the PBS animals. Altogether, these results indicate that the perseveration seen
in PPA treated animals is not likely confounded by these factors.
PPA has many physiological consequences that alter brain function which can
account for the behavioural abnormalities observed in this study. PPA inhibits Na+/ K+
ATPase, increases NMDA receptor sensitivity, promotes intracellular calcium release,
and elevates nitric oxide, all of which can alter normal neuronal function and
transmission (de Mattos-Dutra et ah, 2000; Nishiguchi, Hayashi, Shigetomi, Ueda, &
Tomita, 1997; Wajner, Latini, Wyse, & Dutra-Filho, 2004; Wyse et al., 1998).
Intracellular acidification subsequent to PPA accumulation has widespread effects on
neurotransmitter release involving dopamine, glutamate, norepinepherine, and serotonin
(Cannizzaro, Monastero, Vacca, & Martire, 2003; Remblier et al., 1999; Severson,
Wang, Pieribone, Dohle, & Richerson, 2003), each of which can influence locomotor
activity. Repetitive and stereotyped activity has been shown to result from increased
levels o f dopamine and serotonin in corticostriatal brain circuits, and pH-dependent
release o f these neurotransmitters may explain the increased nose poking behaviour seen
in PPA animals (Langen, Durston, Kas, van Engeland, & Staal, 2011; Langen, Kas,
Staal, van Engeland, & Durston, 2011). Increased serotonin may also help explain the
perseverative effects o f PPA, as serotonin receptor agonists have been shown to impair
learning and memory (Ogren et al., 2008) and reduce social behaviour in rodents
(Gonzalez, Andrews, & File, 1996).
Another pH-dependent effect of PPA is the rapid and reversible closure of gap
junctions, which results in decreased intercellular coupling (Rorig, Klausa, & Sutor,
1996). Gap junctions are necessary for synchronous electrical activity within the brain,
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and animal and human studies have shown that gap junctions are important in the
regulation o f locomotor activity and memory (Juszczak & Swiergiel, 2009). Indeed,
studies using connexin 36 knockout mice and gap junction blockers in rodents have
shown impairments in spatial memory and cognition and increased stereotypy,
repectively (Allen, Fuchs, Jaschonek, Bannerman, & Monyer, 2011; Moore & Grace,
2002). Thus, the increased locomotor behaviour, repetitive nose poking, and
perseveration observed in PPA animals could be a result of the closure of gap junctions.
There are several plausible mechanisms for the perseverative effects of PPA
treatment. PPA has been shown to result in increased astrogliosis and microglia
activation in the hippocampus and white matter suggestive o f an innate
neuroinflammatory process in the absence o f apoptotic neuronal loss (MacFabe et al.,
2007). Evidence from neuropathological conditions such as Parkinson’s and
Alzheimer’s disease, which have similar inflammatory responses, suggests that
neuroinflammation may play a role in impaired cognitive function (Ferretti & Cuello,
2011; Whitton, 2007). Impaired brain function may also result from increased cytokines,
secreted by activated microglia, which is potentially damaging to neurons (Barron,
1995). Consequently, PPA may be inducing a neuroinflammatory response that impairs
the function o f brain structures important for learning and memory, such as the
hippocampus, which may explain the perseveration seen in PPA animals (Leussis &
Bolivar, 2006).
In addition, PPA is known to disrupt fatty acid metabolism in the mitochondria
via the production of the cytotoxin propionyl Coenzyme A and by inhibiting carnitine
function (Brass & Beyerinck, 1988). As a consequence of inhibiting carnitine function,

115
PPA and other fatty acids can accumulate intracellularly with resultant increases in
oxidative stress. Such a diffuse encephalopathic process could lead to cognitive
impairments, not unlike those found in the organic acidemias (Wajner et al., 2004). In
support of this hypothesis, previous work in our laboratory has shown that PPA
treatment results in oxidative stress in widespread brain regions and alters brain lipid
and acylcamitine profiles (MacFabe et al., 2008; Thomas et al., 2010).
PPA and related short chain fatty acids are also capable of inducing extensive
alterations in CNS gene expression, presumably through inhibition of histone
deacetylase or via modulation of second-messenger transduction systems (Parab et al.,
2007). O f particular interest to the current study, short chain fatty acids can induce
phosphorylation o f cyclic AMP response-element-binding protein (CREB), as
demonstrated in both in vitro systems and in rodents using the PPA model (MacFabe et
al., 2007; Shah, Nankova, Parab, & La Gamma, 2006). The transcription factor CREB is
expressed ubiquitously in brain cells and is known to play a vital role in the epigenetic
expression o f genes involved in learning and memory (Carlezon, Duman, & Nestler,
2005). Although not measured here, alterations in CREB-dependent memory pathways
following PPA treatment may underlie the perseverative behavioural effects seen in the
current study.
Results from the present experiment indicate that PPA treatment induced
locomotor, repetitive, and perseverative behaviours reminiscent of the symptoms seen in
ASD. Those with ASD frequently display hyperactivity and repetitive patterns of
behaviour (Matson, Dempsey, & Fodstad, 2009; Murray, 2010), analogous to increased
locomotor activity and repetitive nose poking seen in PPA treated rodents. Furthermore,
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individuals with ASD often display cognitive dysfunction, such as resistance to change
or insistence on sameness and perseverative behaviours (Frith & Happe, 2005; Maes,
Eling, Wezenberg, Vissers, & Kan, 2011). The pattern of persistent nose poking despite
environmental change within the hole-board apparatus observed in animals treated with
PPA is consistent with the cognitive deficits seen in human ASD.
Notably, the proposed underlying mechanisms of PPA-induced behavioural
impairments are theoretically linked to ASD. Abnormalities in several neurotransmitters
systems have been observed in autistic individuals, including dopamine and serotonin
(Chugani, 2004; Previc, 2007). Moreover, serotonin reuptake inhibitors and serotonin
and dopamine antagonists are reported to be effective in reducing repetitive thoughts
and behaviours in children with ASD (McDougle, Kresch, & Posey, 2000; McPheeters,
et al., 2011). An innate neuroinflammatory response, oxidative stress, mitochondrial
dysfunction, and disordered fatty acid metabolism have also been found in autism
(Chauhan, Chauhan, Brown, & Cohen, 2004; Morgan et al., 2010; Rossignol &
Bradstreet, 2008; Vargas et al., 2005) (Wiest et al., 2009).
In summary, ICV infusions of PPA increased locomotor activity and repetitive
behaviour, and induced perseveration in adult male rats. The ability of PPA to induce
widespread changes in the CNS through intracellular acidification or metabolic
dysfunction may offer a potential explanation for the behavioural deficits. Along with
previous findings, the current study supports the use of PPA as a model of ASD as
behavioural and neuropathological effects following PPA treatment resemble the
symptoms and possible underlying pathology o f ASD. An increase in short chain fatty
acids, via alterations in enteric bacteria or impaired fatty acid metabolism, may be a
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plausible environmental factor that triggers or exacerbates ASD in genetically
susceptible sub-populations. Further research is needed to clarify which of the diverse
physiological effects of PPA and other short chain fatty acids are responsible for ASDlike behaviour in rodents.
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4.1 General Discussion
The aims o f the current studies were to (1) assess repetitive and perseverative
behaviours in the hole-board apparatus following PPA treatment and (2) investigate the
effects on behaviour of a low-dose of PPA (0.052 M) in comparison to that of a
previously used dose of PPA (0.26 M). Both objectives were devised with the intention
o f further developing the PPA rodent model of ASD. In Chapter 2, locomotor and nose
poking behaviour were examined in the hole-board apparatus following PPA treatment.
Since this was the first time that the hole-board task was used within the PPA model, all
wells within the apparatus remained empty across infusion days. Results showed that
central infusions o f PPA increased locomotor activity and repetitive nose poking
behaviour in a dose-dependent manner. The experiment in Chapter 3 was designed to
determine if placement o f olfactory stimuli in the centre holes would change the pattern
of hole-board exploration, whether animals demonstrated a selective preference for
soiled or clean bedding, and most importantly whether animals would adapt their
behaviour in response to a change in the environment (i.e., shift their hole preference on
infusion day 7). When bedding was located in the centre holes, both PPA groups and the
PBS group showed an increase in the proportion o f centre nose pokes with a
concomitant decrease in the proportion o f comer and wall nose pokes suggestive o f a
change in the pattern of hole-board exploration in response to olfactory stimuli. All
treatment groups showed a preference for soiled bedding from an unfamiliar male rat
over clean bedding from infusion day 3 through 6. The most interesting finding occurred
on infusion day 7, when PPA animals (regardless o f dose) showed a preserved interest
in the hole containing soiled bedding.
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Results from Chapters 2 and 3 showed a dose-dependent increase in locomotor
activity following PPA treatment. PPA-infused animals also showed an increase in nose
poking behaviour. In contrast, the perseverative effects of PPA occurred regardless of
the dose used. Previous work in our lab has also shown that the behavioural response to
PPA in rodents is differentially influenced by the timing and spacing o f PPA infusions
using the same dose (e.g., 1 infusion a week for 5 weeks versus 2 infusions a day for 7
days) (Foley et al., 2008). Investigation of the dose and timing effects of PPA allows for
delineation of different behavioural phenotypes that occur as a result o f variable PPA
exposure. The fact that the rodent model o f PPA allows for many behavioural and
neuropathological phenotypes is useful given that autism disorders are highly
heterogenous and occur across a spectrum o f symptom severity (Ratajczak, 2011).
Additionally, studying the behavioural response to different PPA regimens might be
analogous to the variable exposure to environmental insults seen in human cases of
autism. Exposure to infectious agents and environmental toxins during critical
developmental periods may trigger ASD in genetically susceptible individuals (Fatemi,
2008). The timing and dose of exposure to these environmental agents may influence the
onset, severity, and lifelong modulation o f autism (Herbert, 2010).
It is unlikely that an animal model will fully replicate the complexity of a human
disease. However, animal models provide a means to explore the neurological,
biochemical, and pathological mechanisms underlying disorders such as autism that
would be impossible to do in humans. Understanding the common underlying
mechanism(s) o f a complex neurodevelopmental disorder through an animal model is
imperative to the development of better diagnosis, prevention, and treatment. Indeed,
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animal models led to effective pharmacological drug therapies used in depression
(Willner & Mitchell, 2002). Similar benefits may be derived from the PPA rodent model
o f autism.
For the PPA rodent model of autism to be useful, effective, and relevant to ASD,
it is important to optimize three types o f validity within the model: face validity,
construct validity, and predictive validity (Crawley, 2007; van der Staay, 2006). Face
validity refers to the extent that the symptoms seen in the animal model are similar to
those of the human disorder. Some autism symptoms, such as language deficits, may be
uniquely human and therefore difficult or impossible to model in rodents. However,
other fundamental symptoms of autism, such as social deficits and repetitive behaviour,
can be more easily replicated using analogous behaviour in rats. For instance, the
current study used total distance traveled as an analog to hyperactivity in autistic human
patients. Central infusions of PPA in the current study produced hyperactivity, repetitive
nose poking, and perseveration consistent with the symptoms observed in patients with
autism (Frith & Happe, 2005; Maes, Eling, Wezenberg, Vissers, & Kan, 2011; Matson,
Dempsey, & Fodstad, 2009; Murray, 2010). In addition, previous work has
demonstrated social impairment, cognitive deficits, and restricted interests in PPAtreated rats congruent with those seen in ASD (MacFabe, Cain, Boon, Ossenkopp, &
Cain, 2011; Shultz et al., 2008, 2009). Taken together, the behavioural effects seen in
PPA-treated animals is similar to autism in humans, providing evidence for the face
validity of the PPA model of autism. It would be interesting to assess whether PPAtreated animals show impairments in social communication as a means of modelling the
language deficits seen in ASD. Crawley (2007) proposed that tests measuring
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vocalizations during social interactions or ultrasonic vocalizations by separated pups
may be useful behavioural tests to evaluate communication deficits in rodents. Future
studies o f the PPA rodent model using communication -related tests would address
another core symptom o f ASD, further validating the model.
In addition to face validity, an optimal animal model should have construct
validity and predictive validity (van der Staay, 2006). Construct validity refers to the
extent that the animal model has a sound theoretical rationale based on the similarity of
the animal model to the underlying causes of the disease. Predictive validity refers to the
extent that the animal model shows an expected response to treatments used in the
human disorder. For instance, if a clinical drug is effective in the treatment of autism,
then the same drug should show a similar response within the animal model.
The evaluation o f the construct validity of the PPA rodent model of autism is
limited because o f a lack of an existing comprehensive theory of the aetiology o f autism.
However, the similarities in the neuropathological, biochemical, and proposed
mechanistic effects o f PPA treatment and human ASD could represent a similar
underlying aetiological process. For instance, PPA promotes intracellular calcium
release, elevates nitric oxide, and increases the synthesis and release of dopamine and
serotonin, all o f which may help explain the increase in locomotor activity and repetitive
behaviour observed in the current study (Nishiguchi, Hayashi, Shigetomi, Ueda, &
Tomita, 1997; Wajner, Latini, Wyse, & Dutra-Filho, 2004). Similarly, individuals with
ASD have been shown to have calcium signalling abnormalities, elevated plasma levels
o f nitric oxide, and aberrations in dopamine and serotonin neurotransmitter systems
(Chugani, 2004; Gargus, 2009; Previc, 2007; Sweeten, Posey, Shankar, & McDougle,
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2004). Examination of brain tissue in rodents following PPA administration also bears
resemblance to findings in human ASD cases. PPA treatment results in
neuroinflammation, impaired glutathione metabolism, and altered fatty acid profiles
reminiscent of the activated microglia, increased oxidative stress, and disordered
mitochondrial fatty acid metabolism observed in human ASD (James et al., 2009;
MacFabe et al., 2007; Rossignol & Bradstreet, 2008; Sajdel-Sulkowska, Lipinski,
Windom, Audhya, & McGinnis, 2008; Thomas et al., 2010; Vargas, Nascimbene,
Krishnan, Zimmerman, & Pardo, 2005). Furthermore, PPA has both
electrophysiological and gastrointestinal effects which can account for the high co
morbidity o f seizures and intestinal disorders in ASD (MacFabe et al., 2007; Mitsui,
Ono, Karaki, & Kuwahara, 2005; Tuchman, Moshe, & Rapin, 2009; White, 2003).
One o f the most common and consistent neuropathological findings in the brain
o f those with ASD is reduced number and size of Purkinje cells in the cerebellum
(Bauman & Kemper, 2005; Fatemi, et al., 2002; Palmen, van Engeland, Hof, & Schmitz,
2004). Cerebellar dysfunction has been linked to reduced exploration and stereotyped
behaviour in MRI studies of children with autism (Pierce & Courchesne, 2001), and
repetitive behaviour and increased activity has been observed in a mouse model of
Purkinje cell loss (Martin, Goldowitz, & Mittleman, 2010). Furthermore, prenatal
exposure to valproic acid in rodents, a derivative of PPA, reproduces the cerebellar
abnormalities associated with ASD (Ingram, Peckham, Tisdale, & Rodier, 2000). Given
the ability of PPA to induce repetitive and stereotyped behaviour in the current study, it
would be interesting to investigate whether Purkinje cell atrophy occurs in the
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cerebellum o f PPA treated rodents. This would support further the construct validity of
the PPA model.
Preliminary evidence exists for the predictive validity o f the PPA model.
Dopamine antagonists have been shown to be effective in reducing some of the
behavioural symptoms in autism (McPheeters et al., 2011). Similarly, work in our lab
has shown a decrease in PPA-induced locomotor behaviour as a result of treatment with
dopamine receptor antagonists (Martins et al., 2008), providing initial support for the
predictive validity o f the model. Assessment of the effects of carnitine supplementation
would be a reasonable next step in addressing the predictive validity o f the PPA rodent
model. Carnitine is essential for the proper metabolism of fatty acids within the
mitochondria (Jones, McDonald, & Borum, 2010), and a relative carnitine deficiency
has been observed in blood plasma of autistic patients (Filipek, Juranek, Nguyen,
Cummings, & Gargus, 2004). A randomized double-blind clinical trial of L-camitine to
treat ASD resulted in significant improvements in several clinical measurements of
autism severity (Geier et al., 2011). Since studies in our lab have shown that PPA
treatment in rodents results in altered plasma acylcamitine profiles similar to those in
ASD (Thomas et al., 2010), future experiments using carnitine treatment in PPA-treated
rats would be useful in assessing the predictive validity of the PPA model.
PPA and related short chain fatty acids may be a possible common underlying
mechanism behind the multi-factorial aspects of ASD. Because PPA has the ability to
cross both the gut-blood and blood-brain barriers, it is a plausible environmental link
between brain, gastrointestinal, and dietary factors seen in ASD (Karuri, Dobrowsky, &
Tannock, 1993). Rather than PPA being a direct cause of autism per se, elevated levels
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of PPA early in development may be an environmental risk factor which can trigger or
exacerbate ASD or ASD related behaviours in genetically susceptible populations. It is
important to note that there are no studies directly measuring PPA and related
metabolites in ASD patients. However, there is some indirect evidence suggestive of
increased PPA in autism, such as impaired fatty acid metabolism (Clark-Taylor &
Clark-Taylor, 2004)

, relative carnitine deficiency (Filipek et al., 2004), and reductions

in essential polyunsaturated fatty acids levels (Vancassel et al., 2001). Moreover,
increases in clostridial bacteria species, which produce PPA, have been observed in the
gut o f autistic patients (Finegold et al., 2002; Parracho, Bingham, Gibson, &
McCartney, 2005).
In conclusion, the present studies provide further support for the PPA rodent
model o f autism. Animals infused with PPA showed hyperactivity, increased repetitive
behaviour, and perseveration consistent with the symptoms seen in human ASD. It is
unclear which o f the diverse effects of short-chain fatty acids are responsible for the
ASD-like behaviour in rodents, and future studies are needed to address this question.
Nevertheless, administration of PPA in rodents does show promise as an animal model
to link the disparate behavioural, metabolic, and gastrointestinal findings in ASD.
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